<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PEN</journal-id>
<journal-id journal-id-type="hwp">sppen</journal-id>
<journal-id journal-id-type="nlm-ta">JPEN J Parenter Enteral Nutr</journal-id>
<journal-title>Journal of Parenteral and Enteral Nutrition</journal-title>
<issn pub-type="ppub">0148-6071</issn>
<issn pub-type="epub">1941-2444</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0148607112446703</article-id>
<article-id pub-id-type="publisher-id">10.1177_0148607112446703</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Invited Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title><italic>Clostridium difficile</italic></article-title>
<subtitle>Epidemiology, Pathogenesis, Management, and Prevention of a Recalcitrant Healthcare-Associated Pathogen</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Badger</surname><given-names>Victor O.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0148607112446703">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ledeboer</surname><given-names>Nate A.</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff2-0148607112446703">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Graham</surname><given-names>Mary Beth</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0148607112446703">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Edmiston</surname><given-names>Charles E.</given-names><suffix>Jr.</suffix></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff3-0148607112446703">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-0148607112446703"><label>1</label>Department of Internal Medicine, Division of Infection Diseases, Medical College of Wisconsin, Milwaukee, Wisconsin</aff>
<aff id="aff2-0148607112446703"><label>2</label>Department of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin</aff>
<aff id="aff3-0148607112446703"><label>3</label>Department of Surgery, Division of Vascular Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin</aff>
<author-notes>
<corresp id="corresp1-0148607112446703">Charles E. Edmiston Jr, PhD, Professor of Surgery, Division of Vascular Surgery, Medical College of Wisconsin, 9200 West Wisconsin Ave, Milwaukee, WI 53226; e-mail: <email>edmiston@mcw.edu</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>11</month>
<year>2012</year>
</pub-date>
<volume>36</volume>
<issue>6</issue>
<fpage>645</fpage>
<lpage>662</lpage>
<history>
<date date-type="received">
<day>5</day>
<month>3</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>5</day>
<month>4</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p><italic>Clostridium difficile</italic> is the leading cause of healthcare-associated infectious diarrhea. Although <italic>C difficile</italic> is part of normal flora in some healthy individuals, patients with selective risk factors are often vulnerable to the toxigenic potential of this virulent healthcare pathogen. The spectrum of <italic>C difficile</italic> infection (CDI) is highly variable, ranging from mild to severe illness, presenting with single to multiple disease recurrences. Current approaches to treatment are based on severity of illness, number of recurrences, and clinical presentation. Oral vancomycin and metronidazole have formed the foundation for treatment of CDI, but therapeutic failures are commonly reported, especially involving hypervirulent clones. Alternative therapies, including newer antimicrobials, probiotics, immunotherapy, and fecal transplantation, have all met with varying degrees of efficacy. Although toxigenic culture (TC) testing from anaerobic culture remains the gold standard, newer technologies, including enzyme immunoassay, common antigen (glutamate dehydrogenase) testing, and real-time polymerase chain reaction (PCR) are less time-consuming and rapid. However, TC and PCR have reported high specificity and sensitivity when compared with other laboratory tests. Because of the significant morbidity and mortality associated with CDI, a high index of suspicion is warranted. Prevention and eradication of CDI require a multidisciplinary approach, including early disease recognition through appropriate surveillance, implementation of effective contact isolation strategies, adherence to environmental controls, judicious hand hygiene, evidence-based treatment, and management that includes antibiotic stewardship, continuous education of healthcare workers, and administrative support.</p>
</abstract>
<kwd-group>
<kwd><italic>Clostridium difficile</italic></kwd>
<kwd>PCR</kwd>
<kwd>healthcare-associated pathogen</kwd>
<kwd>infection control</kwd>
<kwd><italic>Clostridium difficile</italic>–associated diarrhea</kwd>
<kwd>therapy</kwd>
<kwd>antibiotic stewardship</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0148607112446703" sec-type="intro">
<title>Introduction</title>
<p>In 1978, after much speculation, <italic>Clostridium difficile</italic> was identified as the causative organism responsible for pseudomembranous colitis. Today, the organism has evolved into an aggressive healthcare-associated pathogen responsible for a wide spectrum of disease processes broadly classified as <italic>Clostridium difficile</italic>–associated disease (CDAD). During an 8-year period from 1993–2001, the number of hospital discharges with CDAD increased from 85,700 to 148,900 (74% increase). Over a shorter interval from 2001–2005, the number increased more than 100% to 301,200.<sup><xref ref-type="bibr" rid="bibr1-0148607112446703">1</xref>,<xref ref-type="bibr" rid="bibr2-0148607112446703">2</xref></sup> The patient population at risk for CDAD is complex, with patients on average having more than 10 diagnoses compared with non-CDAD case populations, which have only 6.<sup><xref ref-type="bibr" rid="bibr2-0148607112446703">2</xref></sup> At present, it is estimated that <italic>C difficile</italic> is responsible for more than 500,000 disease cases each year, the majority of which are hospital acquired.<sup><xref ref-type="bibr" rid="bibr3-0148607112446703">3</xref></sup> In 2000, more than $1.1 billion was spent in the United States for the treatment of CDADs, and the costs continue to rise rapidly.<sup><xref ref-type="bibr" rid="bibr4-0148607112446703">4</xref></sup> The morbidity associated with this disease process is significant, with more than 9% of hospital admissions for CDAD resulting in death compared with less than 2% for other coded admissions.<sup><xref ref-type="bibr" rid="bibr5-0148607112446703">5</xref></sup> Furthermore, the highest risk group are those patients 85 years and older, which is ominous given the demographic trend of the U.S. population over the next 20 years. The transmission of this organism within our healthcare institutions primarily occurs via the hands of healthcare personnel or by contamination of the hospital environment by these spore-forming microorganisms. Transmission of <italic>C difficile</italic> within the healthcare environment is an example of our collective failure to heed basic infection control policies and practices designed to interrupt or prevent such transmissions. The following review considers 6 separate areas relevant to our understanding of CDAD:</p>
<list id="list1-0148607112446703" list-type="order">
<list-item><p>Historical Perspective and Microbial Ecology</p></list-item>
<list-item><p><italic>Clostridium difficile</italic> Virulence Factors</p></list-item>
<list-item><p>Epidemiology and Clinical Presentation</p></list-item>
<list-item><p>Laboratory Testing, Past and Present</p></list-item>
<list-item><p>Treatment of <italic>Clostridium difficile</italic> Infections</p></list-item>
<list-item><p>Infection Control and Prevention Strategies</p></list-item></list>
</sec>
<sec id="section2-0148607112446703">
<title>Historical Perspective and Microbial Ecology</title>
<p><italic>Clostridium difficile</italic> is an obligate anaerobic, gram-positive, spore-forming bacillus that is generally viewed as a normal part of gut flora in many individuals. The first actual description of a CDAD-like disease process was recorded at Johns Hopkins University in 1892.<sup><xref ref-type="bibr" rid="bibr6-0148607112446703">6</xref></sup> The patient was a 22-year-old woman who underwent surgery by Dr William Osler for resection of a tumor in the gastric pylorus. Early in the postoperative period, she developed severe diarrhea and died on the 15th postoperative day. A subsequent postmortem revealed a pseudomembranous “diphtheritic membrane” seen in the small bowel that upon cytological examination identified the key inflammatory features of CDAD. Several case observations of CDAD-like disease were reported in the literature in the early 20th century, including the first report of pseudomembranous colitis in an animal model following treatment with penicillin.<sup><xref ref-type="bibr" rid="bibr7-0148607112446703">7</xref>,<xref ref-type="bibr" rid="bibr8-0148607112446703">8</xref></sup> Following the introduction of antibiotics in the late 1940s and early 1950s, case reports of pseudomembranous enterocolitis became much more frequent with <italic>Staphylococcus aureus</italic> implicated as the causative organism based on routine stool cultures.<sup><xref ref-type="bibr" rid="bibr9-0148607112446703">9</xref>,<xref ref-type="bibr" rid="bibr10-0148607112446703">10</xref></sup> The next phase in the evolutionary understanding of pseudomembranous colitis occurred in the early 1970s when Upjohn introduced the antianaerobic agent, clindamycin. In 1974, Tedesco published a paper describing a relationship between the drug clindamycin and several patients who developed severe diarrhea while being treated for anaerobic infections.<sup><xref ref-type="bibr" rid="bibr11-0148607112446703">11</xref></sup> In a later prospective study supported in part by Upjohn, investigators found that 21% of patients who received clindamycin developed diarrhea, and upon endoscopic examination, 50% of those individuals exhibited pseudomembranous lesions.<sup><xref ref-type="bibr" rid="bibr7-0148607112446703">7</xref></sup> The characterization of the toxigenic nature of pseudomembranous colitis was reported by investigators at the University of Michigan and in the United Kingdom.<sup><xref ref-type="bibr" rid="bibr12-0148607112446703">12</xref>,<xref ref-type="bibr" rid="bibr13-0148607112446703">13</xref></sup> Eventually, several investigators were able to isolate <italic>C difficile</italic> from the stool of patients with pseudomembranous colitis.<sup><xref ref-type="bibr" rid="bibr14-0148607112446703">14</xref>,<xref ref-type="bibr" rid="bibr15-0148607112446703">15</xref></sup></p>
<p>The gastrointestinal (GI) tract is a complex ecosystem exposed to a constant flow of microbial populations, many of which transit through the length of the bowel without establishing residency or causing disease. The microbial burden in the GI tract ranges from 6.0 log<sub>10</sub> colony-forming units (CFU)/mL in the small intestine to &gt;12.0 log<sub>10</sub> CFU/mL in the lumen of the colon.<sup><xref ref-type="bibr" rid="bibr16-0148607112446703">16</xref>,<xref ref-type="bibr" rid="bibr17-0148607112446703">17</xref></sup> This population represents great genetic diversity that includes 15,000–36,000 different species of bacteria.<sup><xref ref-type="bibr" rid="bibr18-0148607112446703">18</xref></sup> The <italic>Clostridium</italic> are a heterogeneous group of organisms that exist in both the lumen of the bowel and on the epithelial brush-border surface of the large intestines. The natural habitat of <italic>C difficile</italic> is not limited to the human GI tract; in fact, there have been numerous reports of <italic>C difficile</italic> recovery from poultry, sheep, pigs, chickens, goats, and selective bovine populations.<sup><xref ref-type="bibr" rid="bibr19-0148607112446703">19</xref><xref ref-type="bibr" rid="bibr20-0148607112446703"/><xref ref-type="bibr" rid="bibr21-0148607112446703"/>-<xref ref-type="bibr" rid="bibr22-0148607112446703">22</xref></sup> This animal habitat has been proposed as a possible reservoir for human colonization, and providing that appropriate risk factors are present, human disease may occur. Dutch investigators have found that a common ribotype strain 078, which is common in pigs, is also the second most common strain causing disease in humans.<sup><xref ref-type="bibr" rid="bibr23-0148607112446703">23</xref></sup> Canadian investigators have documented that cattle can harbor toxigenic strains of <italic>C difficile</italic>, including the hypervirulent 027 strain.<sup><xref ref-type="bibr" rid="bibr22-0148607112446703">22</xref></sup> Furthermore, <italic>C difficile</italic> has also been recovered from ground beef, ground veal, and processed turkey meat intended for both dogs and cats.<sup><xref ref-type="bibr" rid="bibr24-0148607112446703">24</xref></sup> A recent study has suggested that <italic>C difficile</italic> transmission from a household pet may be more common than previously thought. Weese and colleagues<sup><xref ref-type="bibr" rid="bibr25-0148607112446703">25</xref></sup> found that 10% of dogs and 21% of cats were colonized with ribotype strain 001, a common human pathogen, prior to the emergence of the current epidemic strain. A recent Austrian study that collected fecal samples from pigs, cows, and chickens found several molecular subtypes, including selective ribotypes closely associated with human infection. Although most if not all <italic>C difficile</italic> infections that occur within the healthcare environment are hospital acquired via fecal-oral transmission, the presence of human disease-producing toxigenic ribotypes (including binary toxin producers) recovered from domestic animals offers an intriguing scenario of possible zoonotic transmission.<sup><xref ref-type="bibr" rid="bibr26-0148607112446703">26</xref></sup></p>
<p><italic>Clostridium difficile</italic> colonizes the intestinal tract in approximately 1%−15% of healthy adults, and it has been estimated that colonization in newborns can approach 80%, but rarely does the organism cause disease in this population.<sup><xref ref-type="bibr" rid="bibr27-0148607112446703">27</xref>,<xref ref-type="bibr" rid="bibr28-0148607112446703">28</xref></sup> It is has been suggested that the colon of infants may lack receptors required to interact with the toxins released by the bacteria.<sup><xref ref-type="bibr" rid="bibr29-0148607112446703">29</xref></sup> In healthy adults, the intrinsic combination of a competent (intact) normal intestinal flora and the production of antibodies to toxin A protect against <italic>C difficile</italic> colonization and infection. Antitoxin IgG has been found to be more common in asymptomatic carriers than in patients with active disease.<sup><xref ref-type="bibr" rid="bibr30-0148607112446703">30</xref>,<xref ref-type="bibr" rid="bibr31-0148607112446703">31</xref></sup> Hypothetically, those individuals who are colonized early in life most likely develop an immune memory that has a protective effect through adulthood but wanes in the sixth or seventh decade.</p>
</sec>
<sec id="section3-0148607112446703">
<title><italic>Clostridium difficile</italic> Virulence Factors</title>
<p>Our appreciation of the microbial virulence of <italic>C difficile</italic> is dependent in part on our understanding of the genetic components of the pathogenicity locus and its toxigenic variations. The principal virulence factors associated with CDAD are 2 large molecular weight cytotoxins, toxin A and toxin B, which have enterotoxic and cytotoxic activity. Both toxins can cause significant colonic inflammation and disruption of the epithelial mucosal surface (<xref ref-type="table" rid="table1-0148607112446703">Table 1</xref>). These toxins are encoded in the region of the genome called the pathogenicity locus (PaLoc). This region contains 5 genes—<italic>tcdA, tcdB, tcdC, tcdR</italic>, and <italic>tcdE</italic>—that are responsible for the regulation and synthesis of toxins A (TcdA) and B (TcdB). Two additional genes that are not part of the pathogenicity locus, <italic>cdtA</italic> and <italic>cdtB</italic>, encode the binary toxin. Other important virulence loci include <italic>slpA</italic>, a gene that codes the S-layer proteins (adherence and inflammatory stimulation); genes that code for the extracellular matrix-binding domain; a collagen protease gene; a gene for the surface anchor protein required for covalent attachment to peptidoglycan; a pilus biosynthesis locus involved in fimbrial biosynthesis; and a cluster of genes involved in extracellular polysaccharide synthesis.<sup><xref ref-type="bibr" rid="bibr32-0148607112446703">32</xref></sup> The nontoxigenic <italic>C difficile</italic> strains lack the PaLoc gene locus.</p>
<table-wrap id="table1-0148607112446703" position="float">
<label>Table 1.</label>
<caption>
<p>Microbial Virulence Factors for <italic>Clostridium difficile</italic></p>
</caption>
<graphic alternate-form-of="table1-0148607112446703" xlink:href="10.1177_0148607112446703-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Virulence</th>
<th align="center">Factor Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toxin A</td>
<td>PaLoc (TcdA)—cytotoxic loss of barrier function targets Rho GTPase <sup><xref ref-type="bibr" rid="bibr32-0148607112446703">32</xref><xref ref-type="bibr" rid="bibr33-0148607112446703"/><xref ref-type="bibr" rid="bibr34-0148607112446703"/>-<xref ref-type="bibr" rid="bibr35-0148607112446703">35</xref></sup></td>
</tr>
<tr>
<td>Toxin B</td>
<td>PaLoc (TcdB)—synergistic interaction with toxin A<sup><xref ref-type="bibr" rid="bibr32-0148607112446703">32</xref>,<xref ref-type="bibr" rid="bibr33-0148607112446703">33</xref>,<xref ref-type="bibr" rid="bibr37-0148607112446703">37</xref></sup></td>
</tr>
<tr>
<td>Variant toxin A–/B+</td>
<td>Cardiotoxic—multiple-organ failure<sup><xref ref-type="bibr" rid="bibr33-0148607112446703">33</xref>,<xref ref-type="bibr" rid="bibr41-0148607112446703">41</xref>,<xref ref-type="bibr" rid="bibr42-0148607112446703">42</xref></sup></td>
</tr>
<tr>
<td>Binary toxin (CDT)</td>
<td>Not coded on PaLAC locus, actin-ADP-ribosylating protein, increases clostridial adherence to intestinal cell surface, strains also fluoroquinolone resistant<sup><xref ref-type="bibr" rid="bibr33-0148607112446703">33</xref>,<xref ref-type="bibr" rid="bibr34-0148607112446703">34</xref></sup></td>
</tr>
<tr>
<td>S-layer protein</td>
<td><italic>slpA</italic>— gene encodes cell surface adherence and stimulates inflammation<sup><xref ref-type="bibr" rid="bibr32-0148607112446703">32</xref>,<xref ref-type="bibr" rid="bibr34-0148607112446703">34</xref></sup></td>
</tr>
<tr>
<td>S-anchor proteins</td>
<td>Covalent attachment to peptidogylcan<sup><xref ref-type="bibr" rid="bibr32-0148607112446703">32</xref>,<xref ref-type="bibr" rid="bibr34-0148607112446703">34</xref></sup></td>
</tr>
<tr>
<td>Sporulation/germination</td>
<td>Outer spore coat proteins induce inflammation (peroxiredoxin-1 and chitinase)<sup><xref ref-type="bibr" rid="bibr51-0148607112446703">51</xref></sup></td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The mechanistic action of toxins A and B begins with the binding of the toxin C-terminus to 1 or more target receptors present on the colonic cell surface. Upon binding to the receptor, the toxins are endocytosed and then are acidified prior to translocation into the cell cytosol.<sup><xref ref-type="bibr" rid="bibr33-0148607112446703">33</xref></sup> During this translocation process, the toxins are acidified within an endosome where a pH-induced transformation of both toxins occurs, leading to pore formation in the cell membrane. Once inside the cell, a host cytoplasmic inositol hexaphosphate induces an autocleavage of the toxin mediated by a <italic>C difficile</italic> aspartate protease, resulting in a biologically active toxin.<sup><xref ref-type="bibr" rid="bibr34-0148607112446703">34</xref></sup> Upon entry into the cell, the toxins target Rho GTPases, which plays a central role in a multitude of cellular processes, including organization of the actin cytoskeleton, control of the epithelial barrier function, and the signaling and motility of host immune cells.<sup><xref ref-type="bibr" rid="bibr35-0148607112446703">35</xref></sup> Inactivation of the Rho GTPases by toxin A or B results in shrinkage of the host cell due to disaggregation of the actin cytoskeleton, which results in a loss of structural integrity, leading to apoptosis and cell death. The cumulative effect of this intoxication is the eventual loss of intestinal barrier function. The normally tight junctures between individual epithelial cells are disrupted, allowing migration of granulocytic cells into the intestines, exacerbating the inflammatory response typically seen with colitis. This loss of barrier function leads to increased intestinal permeability and fluid accumulation followed by a secretory diarrhea.<sup><xref ref-type="bibr" rid="bibr36-0148607112446703">36</xref></sup> Although the majority of <italic>C difficile</italic> strains produce both toxins, toxin A has been historically viewed as the major virulence factor because of early experimental studies conducted in hamsters. Hamsters when challenged with purified toxin A display symptoms typical of <italic>C difficile</italic>, including fluid accumulation, inflammation, and necrosis of intestinal tissues. Early studies with purified toxin B, however, did not produce disease unless it was coadministered with toxin A. These early studies suggested that toxin B most likely played a synergistic role in the presence of toxin A.<sup><xref ref-type="bibr" rid="bibr37-0148607112446703">37</xref></sup> Further studies using a rabbit ileal loop model documented that purified toxin A, when administered alone, caused a hemorrhagic disease with increased intestinal permeability, eventually resulting in epithelial cell necrosis. In contrast, toxin B demonstrated no such effect.<sup><xref ref-type="bibr" rid="bibr38-0148607112446703">38</xref></sup> Other animal studies have shown that vaccination with toxin A–specific toxoid is protective to animals when challenged with toxigenic strains. Patients with severe CDAD have been shown to demonstrate a strong humoral response against toxin A.<sup><xref ref-type="bibr" rid="bibr39-0148607112446703">39</xref>,<xref ref-type="bibr" rid="bibr40-0148607112446703">40</xref></sup></p>
<p>However, the occurrence of clinical disease caused by toxin A–negative/B–positive isolates has led to a paradigm shift in our perception of the intrinsic importance of toxin B in CDAD. It is suggested that in selective isolates of <italic>C difficile</italic>, a toxigenic synergistic interaction is not always unnecessary to produce severe disease.<sup><xref ref-type="bibr" rid="bibr33-0148607112446703">33</xref></sup> These toxigenic variants of <italic>C difficile</italic> have been shown to produce a disease of greater severity than the toxin A–positive strains. Studies conducted in a zebrafish embryo intoxication model document that fish treated with purified toxin B demonstrated cardiovascular damage with a 90% drop in systemic blood flow and a 20% drop in heart rate, implying that variants of toxin B may be cardiotoxic.<sup><xref ref-type="bibr" rid="bibr41-0148607112446703">41</xref></sup> These findings suggest that selective toxigenic variants are capable of producing life-threatening systemic (multiple-organ dysfunction) disease in the host.<sup><xref ref-type="bibr" rid="bibr42-0148607112446703">42</xref></sup> Our current recognition of the importance of selective toxin B variants is likely due to genetic variation among clinical isolates, sensitivity of selective animal models to variant strains, and the increased recovery of hypervirulent toxigenic strains (toxin B positive) from patients with CDAD.<sup><xref ref-type="bibr" rid="bibr43-0148607112446703">43</xref></sup></p>
<p>In 2003, a severe outbreak of CDAD occurred in both the United States and Canada due to a clone designated as BI/NAP1/027. Since the original identification of this strain, additional cases have been documented in Europe (England, Belgium, Netherlands, France, Germany, Ireland, Austria, Iceland, Scotland, Luxemburg, Switzerland, Denmark, and Finland), Asia, Africa, and the Middle East. Studies have demonstrated that this strain (027) produces both toxins A and B more quickly and in larger quantities (hyperproduction). This clone is the result of a mutation in the <italic>tcdC</italic> gene, which leads to a nonfunctional TcdC protein. The TcdC protein is responsible for the downregulation of toxin formation. This strain is also capable of producing an actin-ADP-ribosylating toxin called binary toxin (CDT), which is not encoded on the PaLoc, contributing to CDAD by exhibiting cytotoxic activity, inducing the formation of thin microtubules on the outer surface of epithelial cells, and leading to increased clostridial adherence to the colonic cell surface.<sup><xref ref-type="bibr" rid="bibr34-0148607112446703">34</xref></sup> This strain also exhibits a higher germination rate compared with other virulent ribotypes, in addition to expressing resistance to the fluoroquinolones, levofloxacin and moxifloxacin. At present, the B1/NAP1/027 strain accounts for &gt;35% of all strains recovered from <italic>C difficle</italic> infections.<sup><xref ref-type="bibr" rid="bibr44-0148607112446703">44</xref>,<xref ref-type="bibr" rid="bibr45-0148607112446703">45</xref></sup> Several other polymerase chain reaction (PCR) ribotypes have been associated with severe outbreaks, including 053, 106, 078, and 017. Of note, 078 has been associated with infection in young individuals and community-associated infections, and it has been documented as causing infection in swine stocks.<sup><xref ref-type="bibr" rid="bibr23-0148607112446703">23</xref>,<xref ref-type="bibr" rid="bibr46-0148607112446703">46</xref></sup></p>
<p>Other miscellaneous virulence factors likely contributing to CDAD severity include the ability of some strains to demonstrate a higher rate of germination. It has been suggested that strains demonstrating a higher germination rate such as B1/NAP1/027 may contribute to disease recurrence. Relapse rates of 10%−35% have been noted in patients with CDAD.<sup><xref ref-type="bibr" rid="bibr47-0148607112446703">47</xref>,<xref ref-type="bibr" rid="bibr48-0148607112446703">48</xref></sup> In a hypothetical sense, recurrence occurs in strains that exhibit a selective phenotypic advantage over other strains of <italic>C difficile</italic>, especially in the presence of antibiotics, cleaning agents, or germicides.<sup><xref ref-type="bibr" rid="bibr49-0148607112446703">49</xref></sup> A recent study noted that isolates recovered from relapse cases show a significantly higher germination rate compared with isolates recovered from single cases.<sup><xref ref-type="bibr" rid="bibr50-0148607112446703">50</xref></sup> As a final consideration, a recent study investigating the surface layers of <italic>C difficile</italic> endospores determined that 5 distinct coat proteins are present on the outer layer of the clostridial spore. One of these coat proteins, CotE, is a novel bifunctional protein with peroxiredoxin activity at its amino terminus and chitinase activity at its carboxy terminus. Peroxiredoxin 1 is secreted from tumor cells and has been shown to induce inflammatory cytokines in macrophages that promote chronic inflammation. During germination, chitinase provides a source of nutrients to the emerging clostridial cells and may also contribute to the gastrointestinal inflammatory symptoms that accompany <italic>C difficile</italic> infections.<sup><xref ref-type="bibr" rid="bibr51-0148607112446703">51</xref></sup> Although our primary knowledge of the microbial virulence of <italic>C difficile</italic> hinges on deciphering the discrete genetic components of the PaLoc (pathogenicity locus) and its toxigenic variations, other virulence factors such as adherence and motility are likely to be documented as we further probe the biology of this significant healthcare pathogen.</p>
</sec>
<sec id="section4-0148607112446703">
<title>Epidemiology and Clinical Presentation</title>
<p>Since 1978, <italic>C difficile</italic> has been recognized as the causative etiologic agent responsible for antibiotic-associated diarrhea in hospitalized patients.<sup><xref ref-type="bibr" rid="bibr52-0148607112446703">52</xref></sup> In both infants and adults, <italic>C difficile</italic> infection is generally viewed as a healthcare-associated infection. Neonatal colonization is common, but the infants present as asymptomatic despite stool cytotoxin levels that may be similar to those in adults with severe colitis. Surveys in neonatal nurseries and outpatient clinics indicate that more than 50% of healthy infants may have transient colonization of toxicogenic <italic>C difficile</italic>. However, following the first year of life, children become susceptible to <italic>C difficile</italic> colitis.<sup><xref ref-type="bibr" rid="bibr53-0148607112446703">53</xref></sup></p>
<p>To date, almost all antibiotics with the exception aminoglycosides (IV) have been incriminated as a possible driver for <italic>C difficile</italic>–associated diarrhea. Between 1989 and 1992, a strain of <italic>C difficile</italic> highly resistant to clindamycin was implicated in large outbreaks of diarrhea in 4 hospitals in the United States. In 2003, it was observed that an increased frequency of relapse following standard therapy was noted with selective strains of <italic>C difficile</italic>. The changes in disease pathogenesis in both Europe and North America were attributed to a hypervirulent strain of <italic>C difficile</italic> (NAP1/BI/027).<sup><xref ref-type="bibr" rid="bibr54-0148607112446703">54</xref></sup> The ability to produce increased (hyperproduction) amounts of toxins A and B, in the addition to the production of a binary toxin, has played a major role in the enhanced virulence of this microbial pathogen.<sup><xref ref-type="bibr" rid="bibr55-0148607112446703">55</xref></sup> Historically, most strains of <italic>C difficile</italic> demonstrated sensitivity to the fluoroquinolone class of antibiotics.<sup><xref ref-type="bibr" rid="bibr56-0148607112446703">56</xref>,<xref ref-type="bibr" rid="bibr57-0148607112446703">57</xref></sup> Because of the overprescription of these antibiotics in U.S. hospitals, retrospective studies since 2000 have associated fluoroquinolones use to <italic>C difficile</italic> infection (CDI) and the emergence of resistant strains.<sup><xref ref-type="bibr" rid="bibr58-0148607112446703">58</xref>,<xref ref-type="bibr" rid="bibr59-0148607112446703">59</xref></sup> In Quebec, Canada, an increase in the frequency and severity of <italic>C difficile</italic>–associated diarrhea was observed in the early 2000s. A review of 1771 cases from this region published in 2003 documented that the incidence of CDAD per 100,000 cases has increased 4-fold since 1991. Concurrent with the Quebec outbreak, the Centers for Disease Control and Prevention also noted an increasing frequency and severity of <italic>C difficile</italic> infections in the United States, including hospital outbreaks in 6 states.<sup><xref ref-type="bibr" rid="bibr60-0148607112446703">60</xref></sup> Other emerging hypervirulent strains such as PCR078 have been implicated in disease outbreaks, but these strains to date appear to be associated with less complicated disease.<sup><xref ref-type="bibr" rid="bibr55-0148607112446703">55</xref></sup></p>
<p>Historically, <italic>C difficile</italic> infection predominantly affected the elderly and frail, hospital and nursing home patients, and immunosuppressed patients receiving chemotherapy. A prospective cohort study reported in 1998 by Bliss and colleagues<sup><xref ref-type="bibr" rid="bibr61-0148607112446703">61</xref></sup> suggested that patients undergoing tube feeding were at greater risk for acquisition of CDI than non-tube-fed patients. This observation suggested several possible mechanistic scenarios for acquisition, including poor hand hygiene in healthcare workers during tube manipulation, contaminated formulas and delivery system, or the lack of dietary fiber, which may promote an intestinal environment conducive for the growth and persistence of <italic>C difficile</italic>. Recently, <italic>C difficile</italic> infections are being reported with a greater frequency from non-hospital-based settings such as the community. Individuals who are affected in this setting include young and previously healthy individuals who have not been exposed to any healthcare setting or have received antibiotic therapy.<sup><xref ref-type="bibr" rid="bibr54-0148607112446703">54</xref></sup> Close contact with individuals or patients who have CDI appears to be the only evident risk factor in some pediatric cases, underlying the importance of direct person-to-person transmission. An increased awareness of the possibilities of CDI in the atypical setting should warrant early diagnosis and treatment.<sup><xref ref-type="bibr" rid="bibr58-0148607112446703">58</xref></sup></p>
<p>Many well-known risk factors facilitate the acquisition of CDAD (<xref ref-type="table" rid="table2-0148607112446703">Table 2</xref>). Administration of antibiotics that suppress the growth of normal flora remains the most widely recognized and modifiable risk factor associated with CDAD.<sup><xref ref-type="bibr" rid="bibr57-0148607112446703">57</xref>,<xref ref-type="bibr" rid="bibr62-0148607112446703">62</xref></sup> In light of developments over the past 20 years, it is likely that the incidence of <italic>C difficile</italic> will increase as a result of both mandatory reporting of CDI in the United States and the use of more sensitive and rapid molecular-based methods for diagnosis. Early identification of CDI will allow implementation of appropriate infection control measures, in addition to new prevention strategies (such as vaccine or immunotherapy), to reduce the incidence of CDI within the patient care environment.</p>
<table-wrap id="table2-0148607112446703" position="float">
<label>Table 2.</label>
<caption>
<p>Risk Factors Associated With Acquisition of <italic>Clostridium difficile</italic> Infection<sup><xref ref-type="bibr" rid="bibr30-0148607112446703">30</xref>,<xref ref-type="bibr" rid="bibr44-0148607112446703">44</xref>,<xref ref-type="bibr" rid="bibr47-0148607112446703">47</xref>,<xref ref-type="bibr" rid="bibr48-0148607112446703">48</xref>,<xref ref-type="bibr" rid="bibr55-0148607112446703">55</xref>,<xref ref-type="bibr" rid="bibr59-0148607112446703">59</xref>,<xref ref-type="bibr" rid="bibr60-0148607112446703">60</xref>,<xref ref-type="bibr" rid="bibr61-0148607112446703">61</xref>,<xref ref-type="bibr" rid="bibr75-0148607112446703">75</xref></sup></p>
</caption>
<graphic alternate-form-of="table2-0148607112446703" xlink:href="10.1177_0148607112446703-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
</colgroup>
<tbody>
<tr>
<td>Male sex</td>
<td>Age older than 65 years</td>
</tr>
<tr>
<td>Prolonged hospitalization</td>
<td>Prolonged use of antibiotics</td>
</tr>
<tr>
<td>Previous gastrointestinal surgery</td>
<td>Inflammatory bowel disease</td>
</tr>
<tr>
<td>Comorbidity or underlying condition</td>
<td>HIV/AIDS and immunodeficiency</td>
</tr>
<tr>
<td>Neoplastic diseases</td>
<td>Antineoplastic chemotherapies</td>
</tr>
<tr>
<td>Solid organ transplant</td>
<td>Hematopoietic cell transplant</td>
</tr>
<tr>
<td>Malnutrition</td>
<td>Low serum albumin level (&lt;2.5 g/dL)</td>
</tr>
<tr>
<td>Postpyloric tube feeding</td>
<td>Use of proton pump inhibitors</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Acquisition of <italic>C difficile</italic>, like most enteric pathogens, eventually results in a wide spectrum of clinical manifestations both intra-colonic and extra-colonic.<sup><xref ref-type="bibr" rid="bibr61-0148607112446703">61</xref><xref ref-type="bibr" rid="bibr62-0148607112446703"/><xref ref-type="bibr" rid="bibr63-0148607112446703"/><xref ref-type="bibr" rid="bibr64-0148607112446703"/>-<xref ref-type="bibr" rid="bibr65-0148607112446703">65</xref></sup> The clinical presentation can vary from asymptomatic carriage to fulminant peritonitis, which is secondary to perforation of the colon. Commonly, <italic>C difficile</italic> infection presents as diarrhea (usually watery) and abdominal pain. In fulminant cases, it can cause bloody diarrhea, severe systemic sepsis, and toxic megacolon. The patient can die of septic shock and multiorgan failure. Common risk factors include elderly patients who have poor host immunity, individuals on steroids and immunosuppressive therapy, and patients with autoimmune disease and AIDS, who are all at risk for developing fulminant disease.</p>
<sec id="section5-0148607112446703">
<title>Intra-colonic</title>
<list id="list2-0148607112446703" list-type="order">
<list-item><p>Asymptomatic carriers. When individuals are colonized with <italic>C difficile</italic>, they do not exhibit any clinical symptoms such as diarrhea. Many individuals who are culture positive for toxin-producing <italic>C difficile</italic> are asymptomatic carriers. Asymptomatic carriage is very common in hospitalized patients. Epidemiologic studies have reported that 10%−16% of hospital inpatients in high-risk units became carriers after receiving antibiotics. Symptomatic disease is less often seen in carriers despite the observation that most of the <italic>C difficile</italic> isolates are toxin producing. Asymptomatic carriage can be predicted by taking into account certain clinical factors such as recent antibiotic exposure or previous occurrence of CDAD.</p></list-item>
<list-item><p><italic>Clostridium difficile</italic> diarrhea. This usually manifests itself as mild to moderate diarrhea, often associated with crampy abdominal pain. Although malaise and fever are rare, they are not a common component of disease presentation. Symptoms usually occur during or shortly after antibiotic therapy but may be delayed for several weeks. <italic>Clostridium difficile</italic> toxins are normally detected in stool samples even though endoscopic and histological features can be normal in patients with mild disease.<sup><xref ref-type="bibr" rid="bibr63-0148607112446703">63</xref></sup></p></list-item>
<list-item><p><italic>Clostridium difficile</italic> colitis. This presentation is the often the most common clinical manifestation of <italic>C difficile</italic> infection. This is generally a more serious illness with patients presenting with colitis without pseudomembrane formation and may exhibit mild to moderate abdominal pain, nausea, anorexia, and watery diarrhea. Sometimes dehydration and low-grade fever with a systemic polymorphonuclear leukocytosis may occur. A nonspecific diffuse or patchy erythematous colitis without pseudomembrane may be seen during sigmoidoscopy.<sup><xref ref-type="bibr" rid="bibr64-0148607112446703">64</xref></sup></p></list-item>
<list-item><p>Pseudomembranous colitis (PMC). This is the classic manifestation of full-blown <italic>C difficile</italic> colitis and is accompanied by a similar clinical picture as colitis but with more severe symptoms. The diarrhea is often profuse and patients have intense discomfort in either the left or right lower quadrants. At the time of endoscopic examination, pseudomembranes are distributed across the colorectal mucosa and appear as raised yellow plaques measuring about 2–10 mm in diameter, usually in the proximal large bowel. There is often marked leukocytosis with white blood cell (WBC) count in excess of 20,000. Hypoalbuminemia of 3.0 g/dL or lower may be observed in severely ill patients.<sup><xref ref-type="bibr" rid="bibr63-0148607112446703">63</xref></sup></p></list-item>
<list-item><p><italic>Fulminant colitis</italic>. This is the most feared presentation of <italic>C difficile</italic> infection and is seen in 2%−3% of patients. Fulminant colitis accounts for most of the serious complications associated with CDI, including ileus, megacolon, colonic perforation, and death.<sup><xref ref-type="bibr" rid="bibr64-0148607112446703">64</xref>,<xref ref-type="bibr" rid="bibr65-0148607112446703">65</xref></sup> Unfortunately, it is not clear what instigates the sometimes rapid transition from mild to fulminant disease, nor is it known why or which patients will eventually develop this form of the disease. In selective cases, patients who present with benign symptoms will suddenly and rapidly progress to shock. The contributors to disease severity and patient death likely include factors from both the host, such as age, immune status, and comorbidities, and <italic>C difficile</italic>, such as virulence and often antimicrobial resistance.<sup><xref ref-type="bibr" rid="bibr66-0148607112446703">66</xref></sup> Patients with this disease presentation complain of severe lower quadrant or even diffuse abdominal pain, diarrhea, and distension. Some individuals may have high fever, chills, and marked leukocytosis. Diarrhea may be minimal in patients with ileus because secretions accumulate in the dilated atonic colon. Fulminant colitis can lead to toxic megacolon, which on plain abdominal radiograph appears as a markedly dilated colon. In addition, the patient is toxic looking with fever, chills, dehydration, and high WBC count. The small bowel may also appear dilated with air-fluid segments simulating intestinal obstruction or pseudo-obstruction. Signs and symptoms of bowel perforation may be present in some patients with fulminant disease. The incidence of high morbidity and mortality associated with fulminant colitis can be tempered by early aggressive diagnosis and therapy.</p></list-item>
<list-item><p>Recurrent CDAD. This is manifested by the reappearance of diarrhea and other symptoms usually occurring within a few weeks in a patient who had completed treatment with vancomycin or metronidazole.<sup><xref ref-type="bibr" rid="bibr67-0148607112446703">67</xref></sup> The pathophysiology of this recurrent CDAD is not entirely clear, but it is postulated that a persistently altered fecal flora as well as impaired immune response to <italic>C difficile</italic> and/or its toxin may be significant etiologic factors. An adequate and prompt immune response to <italic>C difficile</italic> and/or its toxins represents a key element that influences initial infection and protection against recurrent CDI. It has been estimated that approximately 5%−20% of patients treated for CDAD relapse following successful treatment. Older adults may have an atypical clinical presentation, making diagnosis more challenging. Fever may not be present because fever in an elderly individual generally implies a more serious underlying infection. Acute confusion or altered mental state may be the first symptom. Other nonspecific signs of infection may include weakness and lethargy, frequent falls, anorexia, and loss of physical functional capacity.<sup><xref ref-type="bibr" rid="bibr55-0148607112446703">55</xref></sup></p></list-item></list>
</sec>
<sec id="section6-0148607112446703">
<title>Extra-colonic</title>
<p>Extra-colonic manifestation of <italic>C difficile</italic> infection in a variety of organ systems has been well recognized but perhaps less often encountered. These include small bowel infection, bacteremia, reactive arthritis, and miscellaneous infectious processes, including cellulitis, necrotizing fasciitis, and osteomyelitis. Small bowel CDAD is often seen after a previous surgery and is associated with high mortality. Small bowel CDI is also observed in patients with inflammatory bowel disease (IBD) who have undergone total colectomy (see following section).</p>
</sec>
<sec id="section7-0148607112446703">
<title>Impact of CDI on Inflammatory Bowel Disease</title>
<p>Ulcerative colitis and Crohn’s disease are chronic lifelong immunologically mediated inflammatory processes that present as abdominal pain, bleeding, and diarrhea, and several investigators have suggested an increase in CDI in patients with IBD.<sup><xref ref-type="bibr" rid="bibr68-0148607112446703">68</xref><xref ref-type="bibr" rid="bibr69-0148607112446703"/><xref ref-type="bibr" rid="bibr70-0148607112446703"/><xref ref-type="bibr" rid="bibr71-0148607112446703"/>-<xref ref-type="bibr" rid="bibr72-0148607112446703">72</xref></sup> Past clinical experience suggested that patients with IBD were at little risk for acquiring CDI, and therefore little emphasis was placed on screening for the organism or toxin.<sup><xref ref-type="bibr" rid="bibr73-0148607112446703">73</xref></sup> A retrospective, observational study conducted in Milwaukee found that the rate of CDI-IBD-associated infection as a proportion of institutional burden increased from 7% in 2005 to 16% in 2006 (P <italic>&lt;</italic> .01). The majority of patients were found to have contracted the disease as outpatients. Antibiotic exposure in the patients with CDI-IBD was found to be 61%. Univariate and multivariate analysis revealed that maintenance immunomodulation and disease in the colon were independent risk factors for infection with <italic>C difficile</italic>.<sup><xref ref-type="bibr" rid="bibr69-0148607112446703">69</xref></sup> In a separate retrospective study of CDI in patients with IBD conducted over a 7-year period, there was a doubling of cases in patients admitted with Crohn’s disease (9.5–22.3/1000 admissions) and a tripling of CDI in patients with ulcerative colitis (18.4–57.6/1000 admissions).<sup><xref ref-type="bibr" rid="bibr74-0148607112446703">74</xref></sup> In data obtained from the U.S. Healthcare Cost and Utilization Project Nationwide Inpatient Sample, hospitalized patients with concurrent CDI and IBD had a 4-fold or greater risk of mortality than patients admitted for either CDI or IBD alone.<sup><xref ref-type="bibr" rid="bibr71-0148607112446703">71</xref></sup> In addition to a higher adjusted mortality, patients with CDI-IBD also experience longer hospital stays and a higher rate of GI surgery and endoscopic evaluations than do patients with CDI alone without coexisting IBD. The role of selective interventional strategies has been evaluated as a possible step in decreasing the rate of CDI in patients with IBD. Selective reports have suggested that enhanced infection control practices, early testing, reduction in steroid dosing, and empiric treatment with vancomycin may result in a significant reduction in the number of colectomies among patients with CDI-IBD.<sup><xref ref-type="bibr" rid="bibr63-0148607112446703">63</xref>,<xref ref-type="bibr" rid="bibr75-0148607112446703">75</xref></sup></p>
<p>Patients with IBD who acquire CDI may share many of the same risk factors associated with the non-IBD patient population, including environmental acquisition, prior antibiotic exposure, immunosuppressive therapy, and gastric acid suppressive therapy. An interesting epidemiologic finding associated with CDI acquisition in patients with IBD is that in the majority (&gt;75%) of patients, <italic>C difficile</italic> acquisition occurs in the community environment.<sup><xref ref-type="bibr" rid="bibr68-0148607112446703">68</xref>,<xref ref-type="bibr" rid="bibr74-0148607112446703">74</xref>,<xref ref-type="bibr" rid="bibr75-0148607112446703">75</xref></sup> This is in direct contrast to non-IBD patients who acquire CDI in the hospital environment. The reason for the finding is unknown. A recent study has suggested that a subset of patients with IBD in remission may have a higher carriage rate of <italic>C difficile</italic> than do healthy individuals. The <italic>C difficile</italic> carriage rate in this subset of patients appears to be unrelated to antibiotic exposure or immunosuppressive therapy.<sup><xref ref-type="bibr" rid="bibr76-0148607112446703">76</xref></sup> Although environmental exposure is often viewed as the most important risk factor in healthcare-associated cases of CDI, it would seem reasonable that the acquisition of clostridial spores may occur outside the hospital, but at present, little is known of this mechanistic possibility.</p>
<p>Previous antibiotic exposure is viewed as a potent trigger mechanism in CDI, but in 1 study, 60% of IBD patients who developed CDI did not have exposure to any antibiotics for at least 3 months prior to presentation.<sup><xref ref-type="bibr" rid="bibr77-0148607112446703">77</xref></sup> In another study, the investigators were unable to identify any previous antibiotic exposure in almost 40% of IBD patients who developed CDI.<sup><xref ref-type="bibr" rid="bibr68-0148607112446703">68</xref></sup> Although antibiotic exposure likely plays some role in disease development, the mechanism of how this occurs in the patient with IBD is presently unknown. The role of immunomodulation may actually be a significant risk factor in patients with IBD. Agents such as azathioprine, 6-mercaptopurine, methotrexate, and infliximab have all been associated with an increase in CDI in IBD, especially in patients taking 2 immunosuppressive agents for maintenance therapy.<sup><xref ref-type="bibr" rid="bibr68-0148607112446703">68</xref></sup> Corticosteroids have also been associated with increased risk of CDI relapse in solid organ transplant (SOT) patients.<sup><xref ref-type="bibr" rid="bibr78-0148607112446703">78</xref></sup> In another investigation involving a large cohort population of patients with IBD, combined use of corticosteroids with or without the simultaneous use of immunomodulating drugs was associated with a 3-fold increase in the risk of acquiring a CDI.<sup><xref ref-type="bibr" rid="bibr79-0148607112446703">79</xref></sup></p>
<p>The role of proton pump inhibitors (PPIs) and the acquisition of CDI is a subject of some controversy. Although some studies have reported an increased risk of CDI during PPI therapy, these findings are not universally accepted.<sup><xref ref-type="bibr" rid="bibr77-0148607112446703">77</xref>,<xref ref-type="bibr" rid="bibr80-0148607112446703">80</xref></sup> The PPI connection is intriguing because the disruption of the normal bowel flora has always been viewed as a potential precipitating event in the evolution of <italic>C difficile</italic> acquisition in recurrent disease, but its contributory role in CDI-IBD is at present unresolved. Finally, one should not discount the impact of IBD itself as a significant risk factor for the development of CDI. The relationship between disease severity (IBD) and increased risk of CDI is worthy of consideration. Clayton and colleagues<sup><xref ref-type="bibr" rid="bibr76-0148607112446703">76</xref></sup> have suggested that an “underlying disturbance in innate immunity” may lead to an increased carriage rate of <italic>C difficile</italic> in a subset of patients with IBD, especially those individuals with ulcerative colitis.</p>
<p>Two selective scenarios worthy of mentioning is the relationship of CDI in patients with IBD who develop <italic>C difficile</italic> enteritis and <italic>C difficile</italic> pouchitis. In general, <italic>C difficile</italic> small bowel enteritis is rare, but when it does occur, the mortality has been reported to range between 60% and 83%.<sup><xref ref-type="bibr" rid="bibr81-0148607112446703">81</xref></sup> The clinical presentation includes diarrhea followed by ileus with fluid-engorged loops of small bowel. Although sepsis and fluid shift can be life-threatening, the disease is treatable if the process is noted early. In a report from the Medical College of Wisconsin in Milwaukee, Lundeen and colleagues<sup><xref ref-type="bibr" rid="bibr82-0148607112446703">82</xref></sup> reported on 6 patients who underwent colectomy with ileostomy for severe ulcerative colitis and developed high-volume output (clostridial toxin positive), fever, leukocytosis, and ileus in the postoperative period. Several of these patients (4/6) had a known history of previous CDI prior to colectomy. The authors suggest that clinicians should have a high index of suspicion of enteritis in any patient who has a history of IBD, <italic>C difficile</italic> colitis prior to colectomy, and a troublesome postoperative course. In general, most patients will respond to rapid and aggressive therapy. In the case of severe ulcerative colitis, total proctocolectomy with anal anastomosis is the procedure of choice for patients who require surgery for dysplasia or refractory medical disease. In some instances, <italic>C difficile</italic>–associated pouchitis has been reported to be refractory to broad-spectrum antibiotic therapy.<sup><xref ref-type="bibr" rid="bibr83-0148607112446703">83</xref>,<xref ref-type="bibr" rid="bibr84-0148607112446703">84</xref></sup></p>
<p>Current clinical and epidemiologic findings would suggest that over the past 10 years, there has been a significant increase in the burden of CDI in the IBD patient population. Although many IBD patients share common disease risk factors with non-IBD patient populations, the high mortality rate often associated with CDI in this patient population should trigger a high index of suspicion leading to early and aggressive therapy.</p>
</sec></sec>
<sec id="section8-0148607112446703">
<title>Laboratory Testing, Past and Present</title>
<p>The diagnosis of CDI requires rapid and accurate technologies for individual patient management and prevention of nosocomial transmission. Accurate diagnosis of CDI relies on a combination of clinical history and laboratory tests. Before submitting stool specimens to the laboratory for diagnosis of CDI, several prerequisites must be met (<xref ref-type="table" rid="table3-0148607112446703">Table 3</xref>). Patients submitting specimens for <italic>C difficile</italic> detection should have no other indication for diarrhea, a history of exposure to broad-spectrum antibiotics, and recent hospitalization. Establishment of risk factors meeting these criteria is an important prerequisite for submission of stool to the laboratory for in vitro diagnostics. When met, these submission guidelines can improve the quality and performance (positive predictive value [PPV] and negative predictive value [NPV]) of in vitro test results. Laboratory diagnosis of CDI continues to evolve but can include culture of the bacterium, detection of bacterial toxins, or detection of toxin genes directly from stool. Current laboratory methods include toxigenic culture (TC) and cell cytotoxicity neutralization assay (CCNA), enzyme immunoassay (EIA) for toxin (TcdA or TcdB) or common antigen (glutamate dehydrogenase [GDH]), and real-time PCR.<sup><xref ref-type="bibr" rid="bibr85-0148607112446703">85</xref></sup></p>
<table-wrap id="table3-0148607112446703" position="float">
<label>Table 3.</label>
<caption>
<p>Clinical Prerequisites for <italic>Clostridium difficile</italic> Testing</p>
</caption>
<graphic alternate-form-of="table3-0148607112446703" xlink:href="10.1177_0148607112446703-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
</colgroup>
<tbody>
<tr>
<td>1. History of antibiotic treatment</td>
</tr>
<tr>
<td>2. Exposure to healthcare environment</td>
</tr>
<tr>
<td> a. Healthcare worker</td>
</tr>
<tr>
<td> b. Frequent exposure to medical personnel</td>
</tr>
<tr>
<td> c. Recent hospitalization or stay in long-term care facility</td>
</tr>
<tr>
<td>3. Belonging to a risk group</td>
</tr>
<tr>
<td> a. Immunocompromised</td>
</tr>
<tr>
<td> b. Elderly</td>
</tr>
<tr>
<td> c. Severe gastrointestinal disease</td>
</tr>
<tr>
<td>4. Onset of diarrhea within 2–3 days of hospitalization without exposure to other organisms causing gastrointestinal disease</td>
</tr>
<tr>
<td>5. Diarrhea for more than 3 days without causative agent being identified</td>
</tr>
<tr>
<td>6. Diarrhea as primary symptom</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0148607112446703">
<p>Adapted from Stevens et al.<sup><xref ref-type="bibr" rid="bibr87-0148607112446703">87</xref></sup></p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Anaerobic culture of <italic>C difficile</italic> from stool remains a sensitive method for diagnosis, but acquisition of <italic>C difficile</italic> alone does not diagnose CDI because 4% of healthy adults may carry this organism in their normal intestinal flora, and 20%−25% of <italic>C difficile</italic> strains may be nontoxigenic.<sup><xref ref-type="bibr" rid="bibr86-0148607112446703">86</xref>,<xref ref-type="bibr" rid="bibr87-0148607112446703">87</xref></sup> TC testing from anaerobic culture remains the gold standard for laboratory diagnosis owing to its high sensitivity (94%−100%) and high specificity (99%) (<xref ref-type="table" rid="table4-0148607112446703">Table 4</xref>).<sup><xref ref-type="bibr" rid="bibr85-0148607112446703">85</xref>,<xref ref-type="bibr" rid="bibr87-0148607112446703">87</xref></sup> TC involves isolation of <italic>C difficile</italic> from stool by enriching for spores and inoculating the enriched specimen onto an anaerobic culture medium. This is followed by several days of incubation where typical colonies are identified and isolated. Once confirmed as <italic>C difficile</italic>, strains are tested for expression of TcdB using a modified human foreskin tissue culture cell line and observing for a cytopathic effect.<sup><xref ref-type="bibr" rid="bibr88-0148607112446703">88</xref></sup> Although extremely sensitive and specific, the process is time-consuming and laborious, taking 2–5 days. Several reports also suggest that TC has a high rate of biological false positives in patients who do not have diarrhea, highlighting the importance of only sending CDI testing when clinically indicated.<sup><xref ref-type="bibr" rid="bibr89-0148607112446703">89</xref></sup></p>
<table-wrap id="table4-0148607112446703" position="float">
<label>Table 4.</label>
<caption>
<p>Performance Characteristics of <italic>Clostridium difficile</italic> Laboratory Tests Compared With Toxigenic Culture</p>
</caption>
<graphic alternate-form-of="table4-0148607112446703" xlink:href="10.1177_0148607112446703-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Method</th>
<th align="center">Sensitivity, %</th>
<th align="center">Specificity, %</th>
<th align="center">Positive Predictive Value, %<sup><xref ref-type="table-fn" rid="table-fn3-0148607112446703">a</xref></sup></th>
<th align="center">Negative Predictive Value, %<sup><xref ref-type="table-fn" rid="table-fn3-0148607112446703">a</xref></sup></th>
<th align="center">Assay Time</th>
<th align="center">Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toxigenic culture</td>
<td>94–100</td>
<td>99</td>
<td>NA</td>
<td>NA</td>
<td>2–5 d</td>
<td>~$8</td>
</tr>
<tr>
<td>Cell culture neutralization assay</td>
<td>75–100</td>
<td>100</td>
<td>92</td>
<td>99</td>
<td>2–4 d</td>
<td>~$5</td>
</tr>
<tr>
<td>Toxin A/B EIA</td>
<td>63–92</td>
<td>91–98</td>
<td>48–97</td>
<td>95–98</td>
<td>15–100 min</td>
<td>$10–20</td>
</tr>
<tr>
<td>Glutamate dehydrogenase</td>
<td>87–90</td>
<td>94</td>
<td>63</td>
<td>99</td>
<td>15–100 min</td>
<td>$10–20</td>
</tr>
<tr>
<td><italic>C difficile</italic> NAAT</td>
<td>77–99</td>
<td>94–100</td>
<td>68</td>
<td>99</td>
<td>&lt;1–3 h</td>
<td>$25–50</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0148607112446703">
<p>Based on Eastwood et al.<sup><xref ref-type="bibr" rid="bibr95-0148607112446703">95</xref></sup> EIA, enzyme immunoassay; NA, not applicable; NAAT, nucleic acid amplification.</p>
</fn>
<fn id="table-fn3-0148607112446703">
<label>a</label>
<p>Assumes 10% prevalence of disease.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Unlike TC, CCNA specifically detects TcdB from clinical specimens. For CCNA, fresh stool specimens are submitted to the laboratory and suspended in transport medium. The slurry containing transport medium and stool is filtered to separate bacteria and viruses from the toxin. Stool filtrate is then added in parallel to tissue culture cells with and without anti-TcdB neutralizing antibody. Tissue cultures are then incubated for up to 3 days and the cultures are observed daily for cytopathic effect in one well and for neutralization in a second well containing the filtrate and an antitoxin. Specimens that are negative for <italic>C difficile</italic> toxin B will remain unchanged, whereas specimens that are positive for <italic>C difficile</italic> toxin B will demonstrate cytotoxicity.<sup><xref ref-type="bibr" rid="bibr90-0148607112446703">90</xref></sup> Sensitivity of CCNA varies between 75% and 100% with specificity remaining near 100% (<xref ref-type="table" rid="table4-0148607112446703">Table 4</xref>). Although highly sensitive and specific, CCNA is technically complex and requires 2–4 days for a definitive result. Because of the demand for labor and poor turnaround, few laboratories perform this assay.</p>
<p>Historically, EIAs for toxins A and B have been popular for laboratory practice and clinical care because the tests are simple to perform and results are provided within 2–6 hours. EIAs detect the presence of <italic>C difficile</italic> toxins A and B in stool using antibodies against TcdA and B. Diluted patient specimens are added to microwells coated with toxin-specific monoclonal and polyclonal antibodies, resulting in the formation of conjugated toxin-polyclonal antibody (specific for both toxins) complexes. These complexes remain in the microwells after washing and are detected via a colorimetric reaction. These assays are relatively inexpensive, are easy to perform, and can provide accurate, rapid results. It is important to recognize that the performance of immunoassays can vary widely by product and can also be affected by protocol deviations, improper technique, or specimen handling. The sensitivity of EIAs is 63%−92%, which means that false-negative results can occur (<xref ref-type="table" rid="table4-0148607112446703">Table 4</xref>).<sup><xref ref-type="bibr" rid="bibr91-0148607112446703">91</xref><xref ref-type="bibr" rid="bibr92-0148607112446703"/><xref ref-type="bibr" rid="bibr93-0148607112446703"/>-<xref ref-type="bibr" rid="bibr94-0148607112446703">94</xref></sup> A study of 9 commercially available <italic>C difficile</italic> toxin assays found that sensitivity varied between 66.7% and 91.7%, and specificity varied between 91% and 98%.<sup><xref ref-type="bibr" rid="bibr95-0148607112446703">95</xref></sup> With reports of poor sensitivity of some of these tests, Eastwood and colleagues<sup><xref ref-type="bibr" rid="bibr95-0148607112446703">95</xref></sup> determined the PPV to be 48%−97%, depending on the assay and prevalence of <italic>C difficile</italic>. Variation in sensitivity among EIA assays has been attributed to design of the antibodies that capture the toxin. The immunoassay should not be used as an indicator of response to therapy because results remain positive for extended periods in 25% of successfully treated patients.</p>
<p>A second EIA targets the <italic>C difficile</italic> common antigen, GDH, which is secreted by <italic>C difficile</italic> into the stool.<sup><xref ref-type="bibr" rid="bibr87-0148607112446703">87</xref></sup> GDH is an enzyme, present in most microbes, that converts glutamate to α-ketoglutarate and vice versa. GDH is not specific to <italic>C difficile</italic>, and its presence does not confirm the presence of a strain of <italic>C difficile</italic> containing the PaLoc locus.<sup><xref ref-type="bibr" rid="bibr87-0148607112446703">87</xref></sup> However, the absence of GDH from stool is strongly predicative of the absence of <italic>C difficile</italic>, making it a potential screening assay. Given the insensitivity of toxin A/B EIAs, many laboratories have reported 2-step algorithms (<xref ref-type="fig" rid="fig1-0148607112446703">Figure 1a</xref>) using the presence GDH as a marker for the potential presence of toxigenic <italic>C difficile</italic> in stool.<sup><xref ref-type="bibr" rid="bibr89-0148607112446703">89</xref>,<xref ref-type="bibr" rid="bibr95-0148607112446703">95</xref><xref ref-type="bibr" rid="bibr96-0148607112446703"/><xref ref-type="bibr" rid="bibr97-0148607112446703"/><xref ref-type="bibr" rid="bibr98-0148607112446703"/><xref ref-type="bibr" rid="bibr99-0148607112446703"/>-<xref ref-type="bibr" rid="bibr100-0148607112446703">100</xref></sup> GDH-positive specimens are then confirmed using an assay that specifically detects toxin (toxin A/B EIA or CCNA) or the toxin genes (PCR). Early studies reported sensitivities above 90% and negative predictive values as high as 99%.<sup><xref ref-type="bibr" rid="bibr97-0148607112446703">97</xref><xref ref-type="bibr" rid="bibr98-0148607112446703"/><xref ref-type="bibr" rid="bibr99-0148607112446703"/><xref ref-type="bibr" rid="bibr100-0148607112446703"/><xref ref-type="bibr" rid="bibr101-0148607112446703"/>-<xref ref-type="bibr" rid="bibr102-0148607112446703">102</xref></sup> More recent studies suggest that the sensitivity of GDH is less than initially reported, with sensitivity ranging from 87%−90% depending on the gold standard.<sup><xref ref-type="bibr" rid="bibr95-0148607112446703">95</xref></sup> When compared with CCNA alone, sensitivity of GDH will approach 90%, whereas when compared with the more sensitive TC gold standard, sensitivity of GDH will decrease to approximately 87%. Although the lack of sensitivity is the major limitation, other limitations of a 2-step algorithm can include delays associated with reflex testing to toxin EIA, PCR, or CCNA and poor specificity of the GDH assay.<sup><xref ref-type="bibr" rid="bibr97-0148607112446703">97</xref></sup></p>
<fig id="fig1-0148607112446703" position="float">
<label>Figure 1.</label>
<caption>
<p>(a) Two-step algorithm and (b) 3-step algorithm for diagnosis of <italic>Clostridium difficile</italic> infection (CDI) using glutamate dehydrogenase (GDH) as a screen, followed by toxin A/B confirmation. Discrepant specimens between GDH and toxin A/B are reflexed to nucleic acid amplification (NAAT). EIA, enzyme immunoassay.</p>
</caption>
<graphic xlink:href="10.1177_0148607112446703-fig1.tif"/>
</fig>
<p>Nucleic acid amplification (NAAT) is the newest commercially available method for the diagnosis of CDI, despite being originally described nearly 20 years ago.<sup><xref ref-type="bibr" rid="bibr103-0148607112446703">103</xref><xref ref-type="bibr" rid="bibr104-0148607112446703"/>-<xref ref-type="bibr" rid="bibr105-0148607112446703">105</xref></sup> Current NAATs are formatted in PCR, DNA microarray, and loop-mediated isothermal amplification (LAMP) methods. Although employing different detection systems, all are based on amplifying <italic>C difficile</italic> DNA as a marker of CDI. Currently in the United States, 4 Food and Drug Administration (FDA)–cleared platforms include the GeneOhm C DIFF Assay (BD, Franklin Lakes, NJ), ProGastro Cd (GenProbe, San Diego, CA), Xpert <italic>C difficile</italic> (Cepheid, Sunnyvale, CA), and Illumigene <italic>C difficile</italic> (Meridian, Cincinnati, OH) with many more currently in clinical trials. <xref ref-type="table" rid="table4-0148607112446703">Table 4</xref> contains an overall summary of their characteristics. The GeneOhm CDIFF Assay uses real-time PCR and targets the <italic>tcdB</italic> (toxin B) gene. A result of positive or negative is reported in about 2 hours. Reported sensitivity ranges from 84%−96% and specificity ranges from 94%−99% depending on the gold standard used.<sup><xref ref-type="bibr" rid="bibr88-0148607112446703">88</xref>,<xref ref-type="bibr" rid="bibr97-0148607112446703">97</xref>,<xref ref-type="bibr" rid="bibr103-0148607112446703">103</xref>,<xref ref-type="bibr" rid="bibr106-0148607112446703">106</xref></sup> The ProGastro Cd assay also uses real-time PCR but, unlike the GeneOhm assay, requires extraction of DNA using an automated nucleic acid extractor. ProGastro Cd targets the <italic>tcdB</italic> gene. In a study published by Stamper et al,<sup><xref ref-type="bibr" rid="bibr107-0148607112446703">107</xref></sup> sensitivity and specificity of the ProGastro Cd assay were 77.3% and 99%, respectively, compared with TC. In contrast to the study by Stamper et al, a study by Doing and Hintz<sup><xref ref-type="bibr" rid="bibr108-0148607112446703">108</xref></sup> compared the ProGastro Cd and LAMP to TC and found LAMP was 97.8% sensitive and 99.4% specific, whereas ProGastro Cd PCR was 95.7% sensitive and 100% specific. LAMP generated 2 false-negative and 2 false-positive results, whereas ProGastro Cd PCR produced 2 false negatives. The differences between these 2 studies highlight the impact of study size, patient cohort, and methodology on test variability.</p>
<p>The Cepheid GeneXpert, Xpert <italic>C difficile</italic> assay requires the least technologist hands-on time and is capable of producing actionable results in 45 minutes or less. The assay is performed by placing diluted stool into the Xpert <italic>C difficile</italic> cartridge, closing the cartridge, and placing the cartridge into the GeneXpert instrument. The assay is random access, meaning the specimens can be run as they enter the laboratory, while others are running. Sensitivity of this assay ranges from 94%−100%, and the assay has been reported to be 93%−99% specific.<sup><xref ref-type="bibr" rid="bibr98-0148607112446703">98</xref></sup> The final FDA-cleared NAAT for detection of <italic>C difficile</italic> is the Illumigene <italic>C. difficile</italic> assay. The Illumigene assay differs from the previously described assays in that it targets <italic>tcdA</italic> and does not use real-time PCR to amplify DNA. Instead of PCR, the Illumigene assay uses LAMP, in which the target sequence is amplified at a constant temperature using 2–3 sets of primers and a polymerase with strand displacement activity in addition to a replication activity. The benefit of LAMP is that it is isothermal, eliminating the need for expensive thermocyclers, allowing smaller hospitals the opportunity to use a molecular technology with enhanced sensitivity without the inhibitory cost. In a recent publication, Boyanton et al<sup><xref ref-type="bibr" rid="bibr109-0148607112446703">109</xref></sup> report a sensitivity of 95.2% and a specificity of 96.6% compared with TC. This report suggests that despite the difference in target selection compared with the other FDA-approved assays, the LAMP assay is at least as sensitive and specific as <italic>tcdB</italic> PCRs.</p>
<p>With such diversity of available technologies and performance characteristics, selecting the appropriate laboratory test can be challenging. In 2010, the Society for Healthcare Epidemiology of America (SHEA)<sup><xref ref-type="bibr" rid="bibr110-0148607112446703">110</xref></sup> published guidelines establishing specimen collection requirements and recommending optimal <italic>C difficile</italic> testing based on existing evidence. The SHEA guidelines recommend that testing for <italic>C difficile</italic> only be performed on diarrheal (unformed) stool, unless ileus due to <italic>C difficile</italic> is suspected. The proper stool specimens to be submitted for <italic>C difficile</italic> testing should be watery and take the shape of the collection container. Swab specimens are not acceptable because testing cannot be reliably performed.<sup><xref ref-type="bibr" rid="bibr111-0148607112446703">111</xref></sup> Testing of formed stools and asymptomatic patients is discouraged because a significant proportion of the hospitalized population will be colonized with <italic>C difficile</italic>, and testing of these specimens will decrease specificity and PPV of the assays. Use of molecular assays as a “test of cure” should be avoided for the same reasons that testing of asymptomatic patients should also be avoided.</p>
<p>Laboratories performing <italic>C difficile</italic> testing should not conduct routine testing on multiple specimens from the same diarrheal episode.<sup><xref ref-type="bibr" rid="bibr110-0148607112446703">110</xref>,<xref ref-type="bibr" rid="bibr111-0148607112446703">111</xref></sup> The use of multiple specimens in low-prevalence populations will decrease the specificity of the test while only marginally increasing the sensitivity. Testing methodology should also be carefully considered. Although TC for <italic>C difficile</italic> is the most sensitive technique and is optimal for epidemiological studies, turnaround is poor and few laboratories provide this test. The SHEA guidelines recommend against use of toxin EIAs because of poor sensitivity for circulating strains.<sup><xref ref-type="bibr" rid="bibr110-0148607112446703">110</xref></sup> When the current SHEA guidelines were published, the optimal method with sufficient evidentiary support for <italic>C difficile</italic> testing was a 2-step algorithm combining GDH with toxin EIA testing. The addition of GDH as a screen increased the sensitivity for <italic>C difficile</italic> but alone was not specific enough to sufficiently exclude nontoxigenic strains. This led to development of the 2-step algorithm wherein GDH-positive specimens are confirmed using a toxin EIA or <italic>C difficile</italic> NAAT. Evidence that has emerged since publication of the current SHEA guidelines would suggest that GDH remains insensitive compared with TC and NAAT alone.<sup><xref ref-type="bibr" rid="bibr95-0148607112446703">95</xref>,<xref ref-type="bibr" rid="bibr98-0148607112446703">98</xref></sup></p>
<p>Although many laboratories with existing instrumentation have readily embraced molecular <italic>C difficile</italic> screening, many more remain concerned about the cost of supporting NAATs, the laboratories’ capability of supporting NAAT testing with appropriate turnaround, and a perceived lack of specificity of NAATs. In an effort to contain costs and rule out negative specimens, some laboratories have modified the 2-step algorithm illustrated in <xref ref-type="fig" rid="fig1-0148607112446703">Figure 1a</xref> to replace toxin EIA with NAAT or have modified the 2-step algorithm into a 3-step algorithm (<xref ref-type="fig" rid="fig1-0148607112446703">Figure 1b</xref>). In the 3-step algorithm, the initial step remains a GDH screen. Patients negative by GDH are reported as negative. If the specimen is positive for GDH and toxin A/B, it is interpreted as positive without further action. Discrepant specimens between the GDH and toxin EIA are reflexed to PCR. The major issue with this algorithm is that the initial screen (GDH) used to determine the presence of <italic>C difficile</italic> lacks sensitivity compared with NAAT alone.<sup><xref ref-type="bibr" rid="bibr95-0148607112446703">95</xref>,<xref ref-type="bibr" rid="bibr97-0148607112446703">97</xref></sup> Recent reports indicate that GDH is approximately 87%−90% sensitive compared with TC, indicating that up to 10% of positive patients will be missed using this algorithm.</p>
<p>One final challenge of selecting <italic>C difficile</italic> testing is an increasing requirement for public reporting of <italic>C difficile</italic> rates. In a recent article, Fong et al<sup><xref ref-type="bibr" rid="bibr112-0148607112446703">112</xref></sup> suggest that the downside of public reporting will be a lack of adjustment for case mix and testing methodology. Institutions that have implemented PCR screening for <italic>C difficile</italic> have reported increases in CDI positivity rates of 2- to 3-fold. If public reporting does not allow for rate adjustments based on testing methodology and population prevalence, hospitals may be disadvantaged when performing the most sensitive testing methodologies.</p>
</sec>
<sec id="section9-0148607112446703">
<title>Treatment of <italic>Clostridium difficile</italic> Infections</title>
<p>The spectrum of CDIs can range from mild to severe illness and from single to multiple recurrent episodes. Current approaches to the treatment of CDI vary and are based on the severity of the illness as well as the number of recurrences and clinical presentation. Oral vancomycin and metronidazole have formed the foundation for treatment of CDI for many years, but failures with these agents have been reported. In 2010, SHEA and the Infectious Diseases Society of America (IDSA) published clinical practice guidelines for the diagnosis and management of CDI in adult patients that have become the standard of practice for the treatment of patients presenting with CDIs.<sup><xref ref-type="bibr" rid="bibr110-0148607112446703">110</xref></sup> <xref ref-type="table" rid="table5-0148607112446703">Tables 5</xref> and <xref ref-type="table" rid="table6-0148607112446703">6</xref> report standard and alternative treatment strategies.</p>
<table-wrap id="table5-0148607112446703" position="float">
<label>Table 5.</label>
<caption>
<p><italic>Clostridium difficile</italic> Infection Treatment: Standard Approach Based on SHEA/IDSA Treatment Guidelines<sup><xref ref-type="bibr" rid="bibr110-0148607112446703">110</xref></sup></p>
</caption>
<graphic alternate-form-of="table5-0148607112446703" xlink:href="10.1177_0148607112446703-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">CDI Severity</th>
<th align="center">Definition</th>
<th align="center">Recommended Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asymptomatic carriage</td>
<td>Toxin or PCR positive without diarrhea, ileus, or colitis</td>
<td>None</td>
</tr>
<tr>
<td>Mild to moderate</td>
<td>Toxin or PCR positive with diarrhea</td>
<td/>
</tr>
<tr>
<td> First episode</td>
<td/>
<td>Metronidazole 500 mg by mouth 3 times daily × 10-14 days</td>
</tr>
<tr>
<td> First recurrence</td>
<td/>
<td>Same treatment as used for first episode</td>
</tr>
<tr>
<td> Second recurrence</td>
<td/>
<td>Vancomycin 125 mg by mouth 4 times daily followed by taper (see text)</td>
</tr>
<tr>
<td>Severe</td>
<td>Toxin or PCR positive with diarrhea and ≥1 of the following: WBC &gt;15,000, increase in serum creatinine &gt;50% from baseline</td>
<td>Vancomycin 125 mg by mouth four times daily × 10–14 days</td>
</tr>
<tr>
<td>Severe/complicated</td>
<td>Toxin or PCR positive and ≥1 of the following attributable to CDI: hypotension, ileus, toxic megacolon or pancolitis, ICU admission</td>
<td>Vancomycin 500 mg by mouth (or by rectum if ileus is present) every 6 house plus metronidazole 500 mg intravenously every 8 hours</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0148607112446703">
<p>CDI, <italic>Clostridium difficile</italic> infection; IDSA, Infectious Diseases Society of America; ICU, intensive care unit; PCR, polymerase chain reaction; SHEA, Society for Healthcare Epidemiology of America; WBC, white blood cell.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table6-0148607112446703" position="float">
<label>Table 6.</label>
<caption>
<p>Alternative Approaches for Recurrent CDI</p>
</caption>
<graphic alternate-form-of="table6-0148607112446703" xlink:href="10.1177_0148607112446703-table6.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">CDI Classification</th>
<th align="center">Medication</th>
<th align="center">Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="2">Mild to moderate first episode or first recurrence</td>
<td rowspan="2">Fidaxomycin 200 mg by mouth twice daily × 10-14 days</td>
<td>Clinical cure rate equivalent to oral vancomycin</td>
</tr>
<tr>
<td>Fewer recurrences after treatment than seen with vancomycin</td>
</tr>
<tr>
<td rowspan="2">Mild to moderate third or later recurrence</td>
<td rowspan="2">Vancomycin 125 mg by mouth 4 times daily × 14 days or pulse with taper. Once asymptomatic, treat with rifaxamin 400 mg twice daily × 14 days<sup><xref ref-type="bibr" rid="bibr116-0148607112446703">116</xref></sup></td>
<td>No standard recommendations for dosing of rifaxamin. One study used rifaxamin 400 mg 3 times daily × 14 days followed by 200 mg 3 times daily × 14 days<sup><xref ref-type="bibr" rid="bibr8-0148607112446703">8</xref></sup></td>
</tr>
<tr>
<td>Risk of emerging resistance</td>
</tr>
<tr>
<td>Multiple recurrences</td>
<td>Fecal transplant</td>
<td>Should be considered if all other modalities have been tried and failed</td>
</tr>
<tr>
<td>Severe/complicated</td>
<td>IVIG 400 mg/kg plus standard therapy with oral vancomycin</td>
<td>Should be considered if patient not responding to standard therapy. No standard recommendations for repeat dosing<sup><xref ref-type="bibr" rid="bibr17-0148607112446703">17</xref></sup></td>
</tr>
<tr>
<td/>
<td>Tigecycline 100 mg IV followed by 50 mg IV every 12 hours × 14 days plus standard therapy with oral vancomycin</td>
<td>Anecdotal case reports of success with variable duration</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0148607112446703">
<p>CDI, <italic>Clostridium difficile</italic> infection; IV, intravenous; IVIG, intravenous immunoglobulin.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section10-0148607112446703">
<title>Initial Episode</title>
<p>Metronidazole 500 mg orally 3 times per day for 10–14 days remains the drug of choice for an initial episode of mild to moderate CDI. When comparing efficacy of metronidazole to vancomycin based on disease severity, vancomycin 125 mg orally 4 times per day for 10–14 days has been shown to be superior to treatment with metronidazole in patients presenting with severe disease.<sup><xref ref-type="bibr" rid="bibr113-0148607112446703">113</xref></sup> The main factors that are considered indicative of a severe or complicated course include admission to an intensive care unit, age (&gt;60 years), leukocytosis (&gt;15,000 cells/µL), and an elevated serum creatinine level, which may reflect volume loss and dehydration from diarrhea. For patients who present with very severe, complicated disease, combination therapy with vancomycin 500 mg by mouth 4 times per day and metronidazole 500 mg intravenously every 8 hours is suggested. If the patient is unable to take anything by mouth or has an ileus, a retention enema with vancomycin 500 mg in 100 cc normal saline can be instilled every 6 hours until the patient is able to take medications by mouth.</p>
<p>Because one of the main risk factors for the development of CDI is antibiotic exposure, a question that frequently arises in the course of the initial treatment is whether it is prudent to stop oral metronidazole or vancomycin after 10–14 days if the patient is continuing on antimicrobials for other indications. Although no prospective trials have been done to examine this question specifically, it is the practice of many clinicians to prolong the duration of treatment of CDI until after other antimicrobial regimens have been stopped even if the patient is no longer symptomatic to prevent recurrence. In that scenario, oral vancomycin would be the preferred agent in patients without signs or symptoms of active colitis or diarrhea since metronidazole would be absorbed in small bowel, leading to subtherapeutic levels of drug in the colon and potentially increasing the risk of recurrence.</p>
</sec>
<sec id="section11-0148607112446703">
<title>Recurrent Episodes</title>
<p>It has been estimated that 20%−30% of patients will have a recurrent episode of CDI after initial treatment, and approximately 50% of those individuals will go on to have multiple recurrences.<sup><xref ref-type="bibr" rid="bibr114-0148607112446703">114</xref>,<xref ref-type="bibr" rid="bibr115-0148607112446703">115</xref></sup> For the first recurrence, it is recommended to use the same regimen as the first episode, unless the severity of disease dictates a switch from metronidazole to vancomycin. For the second recurrence and all subsequent recurrences, vancomycin is typically recommended in tapering and pulsed doses (eg, vancomycin 125 mg 4 times a day for 14 days, 125 mg twice daily for 7 days, 125 mg daily for 7 days, 125 mg every other day for 7 days, and 125 mg PO every third day for 2–8 weeks). Spores are only susceptible to killing by antibiotics when they are in a fully vegetative form, and by pulsing vancomycin intermittently, spores are allowed to germinate, therefore making them susceptible to killing. The repetitive cycle of antibiotic-free periods also allows an opportunity for the normal colonic flora to reestablish itself.</p>
<p>Another approach that has been advocated for patients with multiple relapses is the use of rifaximin “chaser” therapy based on an initial study of 8 women with ≥4 recurrent episodes of CDI.<sup><xref ref-type="bibr" rid="bibr116-0148607112446703">116</xref></sup> Each patient was given a 2-week course of rifaximin 400 mg twice daily for 14 days after completing a standard 14-day course of vancomycin. Seven of the 8 patients experienced no further diarrhea recurrence. The patient who had a recurrence responded to a second course of rifaximin therapy, but rifaximin-resistant <italic>C difficile</italic> was recovered after treatment. Multiple other reports using variable doses of rifaximin in small groups of patients have been published showing similar efficacy, but no randomized trials have been performed supporting the routine use of this agent in the treatment of recurrent CDI, and as noted, emerging resistance is a concern.<sup><xref ref-type="bibr" rid="bibr117-0148607112446703">117</xref><xref ref-type="bibr" rid="bibr118-0148607112446703"/>-<xref ref-type="bibr" rid="bibr119-0148607112446703">119</xref></sup></p>
</sec>
<sec id="section12-0148607112446703">
<title>Alternative Antimicrobial Agents</title>
<p>A number of other agents have been studied and used in the treatment of CDI. Fidaxomicin is a macrocyclic antibiotic approved specifically for the treatment of CDI. In preclinical studies, it was found to be more active in vitro than vancomycin against clinical isolates of <italic>C difficile</italic>, including the hypervirulent NAP1/BI/027 strains. The results of the phase 3 clinical trial comparing fidaxomicin to vancomycin in the treatment of patients with either their first episode or first recurrence of CDI were published in 2011.<sup><xref ref-type="bibr" rid="bibr120-0148607112446703">120</xref></sup> The rates of clinical cure after treatment with fidaxomicin were noninferior to those after treatment with vancomycin (88.2% and 85.8%, respectively). Recurrence rates after treatment were the same for both agents when looking at the hypervirulent strain of <italic>C difficile</italic>, but fidaxomicin was associated with a significantly lower rate of recurrent CDI in patients with the non–North American Pulsed Field type 1 strains when compared with vancomycin (15.4% vs 25.3%, respectively). Current data exist only for the treatment of mild to moderate CDI, and no available studies have evaluated patients with multiple recurrences of CDI, patients with underlying IBD, or those patients presenting with fulminate life-threatening disease. A promising property of this agent appears to be a very low rate of in vitro spontaneous resistance of <italic>C difficile</italic> following serial passage in fidaxomicin as compared with reported resistance rates for metronidazole (6.3%) and intermediate resistance rates to vancomycin of 3.1% from patient samples.<sup><xref ref-type="bibr" rid="bibr121-0148607112446703">121</xref>,<xref ref-type="bibr" rid="bibr122-0148607112446703">122</xref></sup></p>
<p>Nitazoxanide has been shown to be equivalent to metronidazole in treating CDI and effective in metronidazole treatment failures. However, the cost of nitazoxanide is significantly more than metronidazole and not recommended as a routine substitute in the treatment of mild to moderate CDI. Data suggest that it may be as effective as vancomycin in treating mild to moderate CDI, but further studies are needed to assess this medication as an alternate in the treatment of severe disease.<sup><xref ref-type="bibr" rid="bibr123-0148607112446703">123</xref></sup> Tigecycline has been reported as a possible adjunctive or alternative therapy for patients with severe refractory CDI.<sup><xref ref-type="bibr" rid="bibr124-0148607112446703">124</xref></sup> Other case reports document successful treatment with tigecycline alone or in combination with other CDI therapies, despite failure of first-line medications. Overall, tigecycline may be an option for severe, complicated disease in critically ill patients when there are few alternative therapeutic options.<sup><xref ref-type="bibr" rid="bibr125-0148607112446703">125</xref></sup></p>
<p>Although the topic of optimal therapeutic efficacy remains questionable, a recent systematic review by Drekonja and colleagues<sup><xref ref-type="bibr" rid="bibr126-0148607112446703">126</xref></sup> analyzed the comparative effectiveness of current <italic>C difficile</italic> treatment strategies. They found that overall, the strength of evidence-based effectiveness of current available antimicrobial agents was generally low to moderate. In their review, they found that fidaxomicin, metronidazole, and vancomycin were generally effective, but no agent demonstrated a clear superiority over the other. Recurrent infection was frequently observed with all agents, but fidaxomicin was associated with fewer episodes of recurrence than vancomycin for non-NAP1 strains. In those patients with severe disease, the evidence-based literature found that neither vancomycin nor metronidazole demonstrated superiority over the other.</p>
</sec>
<sec id="section13-0148607112446703">
<title>Probiotics</title>
<p>The use of probiotics to restore balance to colonic microbiota either in the treatment or prevention of CDI has been the topic of numerous articles. A Cochrane systematic review published in 2008 suggested there is insufficient evidence for the use of probiotics in CDI.<sup><xref ref-type="bibr" rid="bibr127-0148607112446703">127</xref></sup> SHEA/IDSA treatment guidelines also do not recommend use of probiotics in CDI due to limited data and the potential risk of bloodstream infection. Furthermore, a recent report from the Agency for Healthcare Research and Quality (AHRQ)<sup><xref ref-type="bibr" rid="bibr59-0148607112446703">59</xref></sup> suggests that “there is low-strength limited evidence that probiotic intervention is no more effective than placebo for primary prevention of CDI.” Of the probiotics studied to date, <italic>Saccharomyces boulardii</italic> has the most data as a suggestive adjunctive treatment agent in recurrent CDI in adult patients, but more supporting evidence is needed.<sup><xref ref-type="bibr" rid="bibr117-0148607112446703">117</xref>,<xref ref-type="bibr" rid="bibr128-0148607112446703">128</xref></sup></p>
</sec>
<sec id="section14-0148607112446703">
<title>Immunotherapy</title>
<p>The level of immune response to <italic>C difficile</italic> colonization is a major risk factor influencing the magnitude and duration of clinical manifestations. This immune response is mediated predominantly by serum IgG anti–toxin A antibodies.<sup><xref ref-type="bibr" rid="bibr129-0148607112446703">129</xref></sup> Intravenous immunoglobulin (IVIG) has been used as a source of these antibodies primarily in the treatment of refractory or fulminate CDI. A systematic review that addressed the use of oral and intravenous (IV) immunoglobulin for the treatment of CDI surmised that overall, there appeared to be benefits to using IVIG in recurrent severe disease, but further research was needed to clarify the role of immunoglobulin, either IV or oral, in the treatment of CDI.<sup><xref ref-type="bibr" rid="bibr130-0148607112446703">130</xref></sup> A phase 2 randomized, double-blind, placebo-controlled trial of the efficacy of a fully human monoclonal antibody targeted against <italic>C difficile</italic> toxin A (CDA1) plus a second targeted against toxin B (CDB1) in preventing the recurrence of <italic>C difficile</italic> infection was published in 2010.<sup><xref ref-type="bibr" rid="bibr131-0148607112446703">131</xref></sup> All patients receiving antibody or placebo were also treated with either oral vancomycin or metronidazole, and 30% of the patients enrolled reported at least 1 prior episode of CDI. The results of this initial trial showed a lower rate of recurrence of CDI among all patients treated with monoclonal antibodies (7% vs 25%), suggesting that this approach may become an important component in the treatment of <italic>C difficile</italic> infections in the future.</p>
</sec>
<sec id="section15-0148607112446703">
<title>Intestinal Microbiota Transplantation</title>
<p>Intestinal microbiota transplantation (IMT), or fecal transplant, has been used as an alternative therapy for patients with refractory CDI that has failed conventional treatment strategies. IMT involves infusing a suspension of healthy donor stool into the intestine of the patient with CDI to restore the colonic flora.<sup><xref ref-type="bibr" rid="bibr132-0148607112446703">132</xref></sup> Gough et al<sup><xref ref-type="bibr" rid="bibr133-0148607112446703">133</xref></sup> reviewed this topic and found that effectiveness varied by route of instillation, relationship to stool donor, volume of stool given, and treatment before infusion. They reported an overall CDI resolution in 92% of patients receiving IMT with no adverse events, suggesting that this strategy may be a viable approach in patients with refractory disease.</p>
</sec>
</sec>
<sec id="section16-0148607112446703">
<title>Infection Control and Prevention Strategies</title>
<p>The challenges posed by <italic>C difficile</italic> represent some of the most difficult and alarming issues confronting infection control and prevention. The difficulties presented by this organism should serve as an impetus for increased collaboration among healthcare personnel and providers, working closely together to minimize the impact of <italic>C difficile</italic> and promote a safe patient environment. Early recognition of patients who are suspected of having or who are diagnosed with CDI is the primary step in preventing the spread of this epidemiologically significant organism.<sup><xref ref-type="bibr" rid="bibr110-0148607112446703">110</xref></sup> <italic>Clostridium difficile</italic> can spread by direct and indirect contact with the patient or exposure to the patient’s environment. Therefore, patients with CDI should be placed in contact precaution isolation as recommended by the Hospital Infection Control Practice Advisory Panel of the Centers for Disease Control and Prevention (HICPAC/CDC).<sup><xref ref-type="bibr" rid="bibr134-0148607112446703">134</xref></sup> Strict adherence to the components of contact precaution will help to break the chain of infection, making a significant impact on limiting the spread of infection and cross-contamination. The following components of contact precaution should be observed in its entirety for patients suspected or diagnosed with CDI to curtail its spread within the healthcare environment.</p>
<list id="list3-0148607112446703" list-type="order">
<list-item><p><italic>Patient placement</italic>. Ideally, patients diagnosed with CDI should be kept in a private room with a bathroom or commode solely dedicated for their use. When this is not possible, such as in rehabilitation centers or in long-term care facilities, the patient with CDI should be cohorted in a separate room or area of the clinical ward. Once the diarrhea has ceased, the patient can then be moved to a regular room. In a multipatient room setting, maintaining a decent separation between beds is strongly encouraged to prevent inadvertent sharing of items and spreading infection.<sup><xref ref-type="bibr" rid="bibr135-0148607112446703">135</xref></sup></p></list-item>
<list-item><p><italic>The use of personal protective equipment (PPE)</italic>. Incorporating effective and consistent barrier precaution is deemed critical to preventing transmission of spores from patient to healthcare providers and subsequently to other patients. It is important that PPE (gown and gloves) must be put on prior to entering and discarded before leaving the patient’s room.<sup><xref ref-type="bibr" rid="bibr136-0148607112446703">136</xref></sup> Contact with the patient and the patient’s environment often results in high exposure of healthcare workers to vegetative <italic>C difficile</italic> and/or its spores. High-touch surfaces such as bed railings, door knobs, and light switches are often highly contaminated with <italic>C difficile</italic> spores. Consequently, gloves must be put on before contact with patients or their environment and throughout the period of direct or indirect patient care. The gloves must be changed often in accordance with the recommendation for glove use and appropriately discarded after use. Gowns will invariably get contaminated during the course of routine patient care and, therefore, should be disposed of properly.</p></list-item>
<list-item><p><italic>Patient transport</italic>. Unless it is absolutely necessary, transport of patients with CDI from their rooms should be limited as much as possible. Patient transporters should be aware of the patient’s isolation status and use appropriate PPE. The patient’s isolation status should also be communicated to the receiving unit prior to the transport so that the unit personnel are able to accommodate the special needs of the patient.<sup><xref ref-type="bibr" rid="bibr136-0148607112446703">136</xref></sup></p></list-item>
<list-item><p><italic>Patient care equipment, instruments, devices, and the environment</italic>. It is well recognized that <italic>C difficile</italic> spores will contaminate patient care equipment and devices through fecal shedding or through contaminated hands of the patient or healthcare providers. <italic>Clostridium difficile</italic> spores can persist for months within the healthcare environment and be transmitted to patients over a long period of time (months).<sup><xref ref-type="bibr" rid="bibr137-0148607112446703">137</xref></sup> Fecal contamination of surfaces, devices, and materials such as commodes, thermometers, and blood pressure equipment may provide a reservoir for <italic>C difficile</italic> spores to disseminate, leading to transmission throughout the healthcare environment.<sup><xref ref-type="bibr" rid="bibr138-0148607112446703">138</xref></sup> High-touch surfaces and equipment must be thoroughly cleaned and disinfected to remove and/or kill spores. The ability of <italic>C difficile</italic> to survive on inert environmental surfaces demands strict adherence to contact precautionary measures to reduce the risk of cross-contamination and subsequent infection.</p></list-item></list>
<sec id="section17-0148607112446703">
<title>Hand Hygiene</title>
<p>Hand hygiene is universally recognized as a critical component of any effective infection control program, and its role in the prevention and control of <italic>C difficile</italic> is no less important. According to the HICPAC/CDC hygiene guidelines, healthcare providers’ hands are frequently contaminated with <italic>C difficile</italic> following patient contact. After gloves are removed, healthcare providers should wash their hands with soap and water. Although alcohol hand gel products are effective against vegetative cells, they are ineffective against clostridial spores. Numerous studies have documented that judicious compliance to appropriate hand hygiene practice is an effective strategy for reducing the risk of dissemination and acquisition of <italic>C difficile</italic> within the healthcare environment.<sup><xref ref-type="bibr" rid="bibr139-0148607112446703">139</xref>,<xref ref-type="bibr" rid="bibr140-0148607112446703">140</xref></sup> A recent study found that 30% of <italic>C difficile</italic> spores remained on hands of volunteers after using 3 mL of an alcohol-based gel, and these spores could be transferred to a second volunteer just by merely shaking hands.<sup><xref ref-type="bibr" rid="bibr44-0148607112446703">44</xref></sup> To interrupt transmission of <italic>C difficile</italic>, hands should always be washed after caring for a patient with <italic>C difficile</italic> with soap and water to mechanically remove spores.<sup><xref ref-type="bibr" rid="bibr138-0148607112446703">138</xref>,<xref ref-type="bibr" rid="bibr141-0148607112446703">141</xref></sup></p>
</sec>
<sec id="section18-0148607112446703">
<title>Environmental Decontamination</title>
<p>The environment is a critical source of contamination, and it plays a significant role in supporting the spread of infection.<sup><xref ref-type="bibr" rid="bibr137-0148607112446703">137</xref></sup> Because <italic>C difficile</italic> is shed in feces, any surface item or medical device that gets contaminated with feces can act as a source reservoir for the spores and therefore play a role in dissemination of <italic>C difficile</italic>. Spores can persist for months on hard surfaces, with the heaviest contamination observed on room floors and on inert surfaces in the patient’s bathroom. Other possible vehicles for dissemination include electronic thermometers, blood pressure cuffs, bed rails and sheets, call buttons, TV and light controls, and IV and tube-feeding devices.<sup><xref ref-type="bibr" rid="bibr138-0148607112446703">138</xref></sup> As the level of environmental contamination increases, the level of hand contamination of healthcare personnel also increases. The greater the incidence of CDI, the greater the opportunity for disease transmission. Therefore, applying appropriate principles of environmental decontamination is a key component of any effective interventional strategy for interrupting the spread of this organism within the healthcare environment.</p>
<p>Disinfectants used in the healthcare environment include quaternary ammonium compounds and phenolic acid derivatives, neither of which, however, are sporicidal. It is believed that some disinfectants may actually encourage sporulation (changing of the organism from the vegetative form state to the protected spore state). The term <italic>hypersporulation</italic> has been used to denote the propensity of the organism to rapidly change from the vegetative to the spore state. It is thought that contact with some germicides stresses the bacterium so it more readily transitions to the hardy spore form. Although many Environmental Protection Agency (EPA)–registered germicides kill the vegetative form of <italic>C difficile</italic>, only chlorine-based disinfectants and high-concentration vaporized hydrogen peroxide are sporicidal. The problems posed by cleaning with hypochlorite solution (bleach) includes corrosion and pitting of equipment and other surfaces over time as well as triggering respiratory difficulties in workers using the solution.<sup><xref ref-type="bibr" rid="bibr142-0148607112446703">142</xref></sup> Therefore, disinfectant products with EPA registration should be used for daily routine cleaning in the healthcare setting and hypochlorite-based disinfectants used for environmental surface disinfection in those patient care areas where surveillance and epidemiology data indicate ongoing transmission of <italic>C difficile</italic>. The CDC recommends that hospital rooms should be terminally cleaned with bleach when patients are discharged or transferred.<sup><xref ref-type="bibr" rid="bibr137-0148607112446703">137</xref></sup></p>
</sec>
<sec id="section19-0148607112446703">
<title>Surveillance</title>
<p>Active surveillance of CDI should be an integral component of the institutional infection control program. Surveillance should focus on determining the hospital burden (incidence) of CDI (including community-acquired CDI) on a unit-specific basis. An active surveillance program should also monitor data on morbidity and mortality, especially on medical and surgical services that manage patients with IBD. Although most healthcare institutions lack the necessary resources to type (ribotypes) specific strains that are present within the institution, data on regional variation can often be obtained from nationwide surveillance programs supported by the CDC or state affiliates. Simply tracking the burden of CDI in selective units within the hospital can be beneficial in developing appropriate and effective interventional control strategies. Although routine surveillance is a costly and labor-intensive endeavor, innovative electronic surveillance programs are now available that rapidly identify <italic>C difficile</italic> cases within targeted patient populations, allowing for the implementation of timely interventions.<sup><xref ref-type="bibr" rid="bibr143-0148607112446703">143</xref></sup></p>
</sec>
<sec id="section20-0148607112446703">
<title>Antibiotic Stewardship</title>
<p>The judicious and appropriate use of antibiotics under the umbrella of an antimicrobial stewardship program can play an important role in the overall infection control and prevention strategies for <italic>C difficile</italic>.<sup><xref ref-type="bibr" rid="bibr138-0148607112446703">138</xref>,<xref ref-type="bibr" rid="bibr144-0148607112446703">144</xref><xref ref-type="bibr" rid="bibr145-0148607112446703"/>-<xref ref-type="bibr" rid="bibr146-0148607112446703">146</xref></sup> Because CDI can almost exclusively be linked to prior antibiotic use, development of a robust healthcare facility stewardship program to ensure appropriate antibiotic use is regarded as an important intervention for the control of CDI. Virtually all antibiotics produce disruption of the host normal flora but differ in their capability to cause collateral damage to the patient’s gastrointestinal flora. There are 2 key considerations when evaluating the risk for CDI produced by a particular antibiotic. The first is the level of risk that a selective antibiotic may pose to a patient receiving antimicrobial therapy and is often categorized as low, intermediate, or high. The next consideration is the number of days that the patient will be at risk for the development of CDI. Days at risk for potential colonization occur from the time the initial antibiotic dose is given extending up to 10 days after discontinuation of the antibiotic. A patient who receives a narrow-spectrum antibiotic for less than 1 day is considered as being at low risk. In contrast, if the same patient were to receive surgical prophylaxis with an unnecessary broad-spectrum antibiotic, the level of risk for developing CDI would move from low to high without additional clinical benefit from the inappropriate antibiotic.<sup><xref ref-type="bibr" rid="bibr136-0148607112446703">136</xref></sup> Extending surgical prophylaxis with multiple doses beyond 24 hours postoperatively will also increase the risk of CDI.<sup><xref ref-type="bibr" rid="bibr146-0148607112446703">146</xref></sup> Therefore, prolonged inappropriate use of a broad-spectrum regimen is a critical determinant of collateral damage that should be prevented.<sup><xref ref-type="bibr" rid="bibr145-0148607112446703">145</xref>,<xref ref-type="bibr" rid="bibr146-0148607112446703">146</xref></sup> Whenever possible, patients should undergo de-escalation therapy, transitioning to a narrower spectrum agent once culture and sensitivity laboratory values are available. The role of the antimicrobial stewardship program is to serve as a vanguard, optimizing the use of the right drug, for the right purpose, and for the right duration of time in a bid to promote judicious use of the antimicrobial agent.<sup><xref ref-type="bibr" rid="bibr146-0148607112446703">146</xref></sup></p>
</sec>
</sec>
<sec id="section21-0148607112446703" sec-type="conclusions">
<title>Conclusion</title>
<p><italic>Clostridium difficile</italic> infections are the leading cause of healthcare-associated infectious diarrhea. Although <italic>C difficile</italic> is part of normal flora in some individuals, patients with selective risk factors are highly vulnerable to the toxigenic potential of this virulent microorganism. Because of the significant morbidity and at times mortality associated with CDI, knowledge of the epidemiology of <italic>C difficile</italic> in combination with a high index of suspicion within susceptible patient populations is warranted. Successful prevention and eradication of CDI require a multidisciplinary approach that includes early recognition through appropriate surveillance, implementation of contact precautions (isolation), monitoring adherence to environmental controls, judicious hand hygiene, evidence-based treatment and management, a focused antibiotic stewardship program, continuous education of healthcare workers, and the support of the hospital (top-down) leadership.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: none declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0148607112446703">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ricciardi</surname><given-names>R</given-names></name>
<name><surname>Rothenberg</surname><given-names>DA</given-names></name>
<name><surname>Madoff</surname><given-names>RD</given-names></name>
<name><surname>Baxter</surname><given-names>NN</given-names></name>
</person-group>. <article-title>Increasing prevalence and severity of <italic>Clostridium difficile</italic> colitis in hospitalized patients in the United States</article-title>. <source>Arch Surg</source>. <year>2007</year>;<volume>142</volume>:<fpage>624</fpage>-<lpage>631</lpage>.</citation>
</ref>
<ref id="bibr2-0148607112446703">
<label>2.</label>
<citation citation-type="gov">
<person-group person-group-type="author">
<name><surname>Elixhauser</surname><given-names>A</given-names></name>
<name><surname>Jhung</surname><given-names>MA</given-names></name>
</person-group>. <source><italic>Clostridium difficile</italic>–Associated Disease in US Hospitals, 1993-2005</source>. Healthcare Cost and Utilization Project, Statistical Brief 50. <publisher-loc>Rockville, MD</publisher-loc>: <publisher-name>Agency for Healthcare Research and Quality</publisher-name>; <year>2008</year>. <ext-link ext-link-type="uri" xlink:href="http://www.hcup-us.ahrg.gov/report/statbrief/sb50.pdf">www.hcup-us.ahrg.gov/report/statbrief/sb50.pdf</ext-link></citation>
</ref>
<ref id="bibr3-0148607112446703">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kuehn</surname><given-names>BM</given-names></name>
</person-group>. <article-title>Scientists seek strategies to prevent <italic>Clostridium difficile</italic> infections</article-title>. <source>JAMA</source>. <year>2011</year>;<volume>306</volume>:<fpage>1849</fpage>-<lpage>1850</lpage>.</citation>
</ref>
<ref id="bibr4-0148607112446703">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kyne</surname><given-names>L</given-names></name>
<name><surname>Hamel</surname><given-names>MB</given-names></name>
<name><surname>Poavaram</surname><given-names>R</given-names></name>
<name><surname>Kelly</surname><given-names>CP</given-names></name>
</person-group>. <article-title>Healthcare costs and mortality-associated with nosocomial diarrhea due to <italic>Clostridium difficile</italic></article-title>. <source>Clin Infect Dis</source>. <year>2002</year>;<volume>34</volume>:<fpage>346</fpage>-<lpage>353</lpage>.</citation>
</ref>
<ref id="bibr5-0148607112446703">
<label>5.</label>
<citation citation-type="gov">
<collab>Hospital stays involving</collab> <article-title><italic>C difficile</italic> infections leveled off after 300 percent increase since 1993</article-title>. AHRQ News and Numbers. <month>January</month> <day>25</day>, <year>2012</year>. <ext-link ext-link-type="uri" xlink:href="http://www.ahrq.gov/news/nn/nn012512.htm">www.ahrq.gov/news/nn/nn012512.htm</ext-link></citation>
</ref>
<ref id="bibr6-0148607112446703">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Finney</surname><given-names>JMT</given-names></name>
</person-group>. <article-title>Gastro-enterostomy for cicatrizing ulcer of the pylorus</article-title>. <source>Bull Johns Hopkins Hosp</source>. <year>1893</year>;<volume>4</volume>:<fpage>53</fpage>.</citation>
</ref>
<ref id="bibr7-0148607112446703">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gerding</surname><given-names>DN</given-names></name>
</person-group>. <article-title><italic>Clostridium difficile</italic> 30 years on: what has, or has not, changed and why?</article-title> <source>Int J Antimicrob Agents</source>. <year>2009</year>;<volume>33</volume>:<fpage>S2</fpage>-<lpage>S8</lpage>.</citation>
</ref>
<ref id="bibr8-0148607112446703">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hambre</surname><given-names>DM</given-names></name>
<name><surname>Raki</surname><given-names>G</given-names></name>
<name><surname>McKnee</surname><given-names>CM</given-names></name>
<name><surname>MacPhillamy</surname><given-names>HB</given-names></name>
</person-group>. <article-title>Toxicity of penicillin as prepared for clinical use</article-title>. <source>Am J Med Sci</source>. <year>1943</year>;<volume>206</volume>:<fpage>642</fpage>-<lpage>653</lpage>.</citation>
</ref>
<ref id="bibr9-0148607112446703">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wakefield</surname><given-names>RD</given-names></name>
<name><surname>Sommers</surname><given-names>SD</given-names></name>
</person-group>. <article-title>Fatal membranous staphylococcal enteritis in surgical patients</article-title>. <source>Ann Surg</source>. <year>1953</year>;<volume>138</volume>:<fpage>249</fpage>.</citation>
</ref>
<ref id="bibr10-0148607112446703">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hummel</surname><given-names>RP</given-names></name>
<name><surname>Altemeier</surname><given-names>WA</given-names></name>
<name><surname>Hill</surname><given-names>EQ</given-names></name>
</person-group>. <article-title>Iatrogenic staphylococcal enterocolitis</article-title>. <source>Ann Surg</source>. <year>1964</year>;<volume>160</volume>:<fpage>551</fpage>.</citation>
</ref>
<ref id="bibr11-0148607112446703">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tedesco</surname><given-names>FJ</given-names></name>
<name><surname>Barton</surname><given-names>RW</given-names></name>
<name><surname>Alpers</surname><given-names>DH</given-names></name>
</person-group>. <article-title>Clindamycin-associated colitis: a prospective study</article-title>. <source>Ann Intern Med</source>. <year>1974</year>;<volume>81</volume>:<fpage>429</fpage>-<lpage>433</lpage>.</citation>
</ref>
<ref id="bibr12-0148607112446703">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rifkin</surname><given-names>GD</given-names></name>
<name><surname>Fekety</surname><given-names>FR</given-names></name>
<name><surname>Silva</surname><given-names>J</given-names></name>
</person-group>. <article-title>Antibiotic-induced colitis implication of a toxin neutralized by <italic>Clostridium sordelli</italic> antitoxin</article-title>. <source>Lancet</source>. <year>1977</year>;<volume>2</volume>:<fpage>1103</fpage>-<lpage>1106</lpage>.</citation>
</ref>
<ref id="bibr13-0148607112446703">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Larson</surname><given-names>HE</given-names></name>
<name><surname>Price</surname><given-names>AB</given-names></name>
</person-group>. <article-title>Pseudomembranous colitis: presence of clostridial toxin</article-title>. <source>Lancet</source>. <year>1977</year>;<volume>2</volume>:<fpage>1312</fpage>-<lpage>1314</lpage>.</citation>
</ref>
<ref id="bibr14-0148607112446703">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>George</surname><given-names>WL</given-names></name>
<name><surname>Sutter</surname><given-names>VL</given-names></name>
<name><surname>Goldstein</surname><given-names>EJ</given-names></name>
<name><surname>Ludwig</surname><given-names>SL</given-names></name>
<name><surname>Finegold</surname><given-names>SM</given-names></name>
</person-group>. <article-title>Etiology of antimicrobial-agent-associated colitis</article-title>. <source>Lancet</source>. <year>1978</year>;<volume>1</volume>:<fpage>802</fpage>-<lpage>803</lpage>.</citation>
</ref>
<ref id="bibr15-0148607112446703">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Larson</surname><given-names>HE</given-names></name>
<name><surname>Price</surname><given-names>AB</given-names></name>
<name><surname>Honour</surname><given-names>P</given-names></name>
<name><surname>Borriello</surname><given-names>SP</given-names></name>
</person-group>. <article-title><italic>Clostridium difficile</italic> and the etiology of pseudomembranous colitis</article-title>. <source>Lancet</source>. <year>1978</year>;<volume>1</volume>:<fpage>1063</fpage>-<lpage>1066</lpage>.</citation>
</ref>
<ref id="bibr16-0148607112446703">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Savage</surname><given-names>DC</given-names></name>
</person-group>. <article-title>The microbial flora in the gastrointestinal tract</article-title>. <source>Prog Clin Biol Res</source>. <year>1981</year>;<volume>77</volume>:<fpage>893</fpage>-<lpage>908</lpage>.</citation>
</ref>
<ref id="bibr17-0148607112446703">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Edmiston</surname><given-names>CE</given-names></name>
<name><surname>Avant</surname><given-names>GR</given-names></name>
<name><surname>Wilson</surname><given-names>FA</given-names></name>
</person-group>. <article-title>Anaerobic bacterial population on normal and diseased human biopsy tissue obtained during colonoscopy</article-title>. <source>Appl Environ Microbiol</source>. <year>1982</year>;<volume>43</volume>:<fpage>1173</fpage>-<lpage>1181</lpage>.</citation>
</ref>
<ref id="bibr18-0148607112446703">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eckburg</surname><given-names>PB</given-names></name>
<name><surname>Bik</surname><given-names>EM</given-names></name>
<name><surname>Berstein</surname><given-names>CN</given-names></name>
</person-group>. <article-title>Diversity of the human intestinal microbial flora</article-title>. <source>Science</source>. <year>2005</year>;<volume>5728</volume>:<fpage>1635</fpage>-<lpage>1638</lpage>.</citation>
</ref>
<ref id="bibr19-0148607112446703">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Al Saif</surname><given-names>N</given-names></name>
<name><surname>Brazier</surname><given-names>JS</given-names></name>
</person-group>. <article-title>The distribution of <italic>Clostridium difficile</italic> from the environment of South Wales</article-title>. <source>J Med Microbiol</source>. <year>1996</year>;<volume>45</volume>:<fpage>133</fpage>-<lpage>137</lpage>.</citation>
</ref>
<ref id="bibr20-0148607112446703">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Songer</surname><given-names>JG</given-names></name>
<name><surname>Post</surname><given-names>KW</given-names></name>
<name><surname>Larson</surname><given-names>DI</given-names></name>
<name><surname>Jost</surname><given-names>H</given-names></name>
<name><surname>Glock</surname><given-names>RD</given-names></name>
</person-group>. <article-title>Infection of neonatal swine with <italic>Clostridium difficile</italic></article-title>. <source>Swine Health Prod</source>. <year>2000</year>;<volume>8</volume>:<fpage>185</fpage>-<lpage>189</lpage>.</citation>
</ref>
<ref id="bibr21-0148607112446703">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Simango</surname><given-names>C</given-names></name>
</person-group>. <article-title>Prevalence of <italic>Clostridium difficile</italic> in a rural community in Zimbabwe</article-title>. <source>Trans R Soc Trop Med Hyg</source>. <year>2006</year>;<volume>100</volume>:<fpage>1146</fpage>-<lpage>1150</lpage>.</citation>
</ref>
<ref id="bibr22-0148607112446703">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rodriquez-Palacios</surname><given-names>A</given-names></name>
<name><surname>Stampfli</surname><given-names>HR</given-names></name>
<name><surname>Duffield</surname><given-names>T</given-names></name>
<name><surname>Peregrine</surname><given-names>AS</given-names></name>
<name><surname>Trotz-Williams</surname><given-names>LA</given-names></name>
<name><surname>Arroyo</surname><given-names>LG</given-names></name>
</person-group>. <article-title><italic>Clostridium difficile</italic> PCR ribotypes in calves</article-title>. <source>Can Emerg Infect Dis</source>. <year>2006</year>;<volume>12</volume>:<fpage>1730</fpage>-<lpage>1736</lpage>.</citation>
</ref>
<ref id="bibr23-0148607112446703">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goorhuis</surname><given-names>A</given-names></name>
<name><surname>Bakker</surname><given-names>D</given-names></name>
<name><surname>Corver</surname><given-names>J</given-names></name>
<name><surname>Debast</surname><given-names>SB</given-names></name>
<name><surname>Harmanus</surname><given-names>C</given-names></name>
<name><surname>Notermans</surname><given-names>DW</given-names></name>
</person-group>. <article-title>Emergence of <italic>Clostridium difficile</italic> infection due to a new hypervirulent strain, polymerase chain reaction type 078</article-title>. <source>Clin Infect Dis</source>. <year>2008</year>;<volume>47</volume>:<fpage>1162</fpage>-<lpage>1170</lpage>.</citation>
</ref>
<ref id="bibr24-0148607112446703">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weese</surname><given-names>JS</given-names></name>
<name><surname>Rousseau</surname><given-names>J</given-names></name>
<name><surname>Arroyo</surname><given-names>I</given-names></name>
</person-group>. <article-title>Bacteriological evaluation of commercial canine and feline raw diets</article-title>. <source>Can Vet J</source>. <year>2005</year>;<volume>46</volume>:<fpage>513</fpage>-<lpage>516</lpage>.</citation>
</ref>
<ref id="bibr25-0148607112446703">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weese</surname><given-names>JSR</given-names></name>
<name><surname>R</surname><given-names>Finley</given-names></name>
<name><surname>Reid-Smith</surname><given-names>RR</given-names></name>
<name><surname>N</surname><given-names>Janecko</given-names></name>
<name><surname>Rousseau</surname><given-names>I</given-names></name>
</person-group>. <article-title>Evaluation of <italic>Clostridium difficile</italic> in dogs and other household environments</article-title>. <source>Epidemiol Infect</source>. <year>2009</year>;<volume>38</volume>:<fpage>1100</fpage>-<lpage>1104</lpage>.</citation>
</ref>
<ref id="bibr26-0148607112446703">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Indra</surname><given-names>A</given-names></name>
<name><surname>Lasnig</surname><given-names>H</given-names></name>
<name><surname>Baliko</surname><given-names>N</given-names></name>
<name><surname>Much</surname><given-names>P</given-names></name>
<name><surname>Fiedler</surname><given-names>A</given-names></name>
<name><surname>Huhulescu</surname><given-names>S</given-names></name>
</person-group>. <article-title><italic>Clostridium difficile</italic>: a new zoonotic agent</article-title>. <source>Wien Klin Wochenschr</source>. <year>2009</year>;<volume>121</volume>:<fpage>91</fpage>-<lpage>95</lpage>.</citation>
</ref>
<ref id="bibr27-0148607112446703">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kelly</surname><given-names>CP</given-names></name>
<name><surname>Pothoulakis</surname><given-names>C</given-names></name>
<name><surname>LaMont</surname><given-names>JT</given-names></name>
</person-group>. <article-title><italic>Clostridium difficile</italic> colitis</article-title>. <source>N Engl J Med</source>. <year>1994</year>;<volume>330</volume>:<fpage>257</fpage>-<lpage>262</lpage>.</citation>
</ref>
<ref id="bibr28-0148607112446703">
<label>28.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Noren</surname><given-names>T</given-names></name>
</person-group>. <article-title><italic>Clostridium difficile</italic> and the disease it causes</article-title>. In: <person-group person-group-type="editor">
<name><surname>Mullany</surname><given-names>P</given-names></name>
<name><surname>Roberts</surname><given-names>AP</given-names></name>
</person-group>, eds. <source><italic>Clostridium difficile</italic>: Methods and Protocols</source>. <publisher-loc>Totowa, NJ</publisher-loc>: <publisher-name>Humana</publisher-name>; <year>2010</year>:<fpage>9</fpage>-<lpage>35</lpage>.</citation>
</ref>
<ref id="bibr29-0148607112446703">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dubberke</surname><given-names>ER</given-names></name>
<name><surname>Haslam</surname><given-names>DB</given-names></name>
<name><surname>Lanza</surname><given-names>C</given-names></name><etal/>
</person-group>. <article-title>The ecology and pathobiology of <italic>Clostridium difficile</italic> infections: an interdisciplinary challenge</article-title>. <source>Zoonoses Public Health</source>. <year>2011</year>;<volume>58</volume>:<fpage>4</fpage>-<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr30-0148607112446703">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leffeler</surname><given-names>DA</given-names></name>
<name><surname>Lamont</surname><given-names>JT</given-names></name>
</person-group>. <article-title>Treatment of <italic>Clostridium difficile</italic>–associated disease</article-title>. <source>Gastroenterology</source>. <year>2009</year>;<volume>136</volume>:<fpage>1899</fpage>-<lpage>1912</lpage>.</citation>
</ref>
<ref id="bibr31-0148607112446703">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Blondeau</surname><given-names>JM</given-names></name>
</person-group>. <article-title>What have we learned about antimicrobial use and the risk of <italic>Clostridium difficile</italic>–associated diarrhea?</article-title> <source>J Antimicrob Chemother</source>. <year>2009</year>;<volume>63</volume>:<fpage>238</fpage>-<lpage>242</lpage>.</citation>
</ref>
<ref id="bibr32-0148607112446703">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sebaihia</surname><given-names>M</given-names></name>
<name><surname>Wren</surname><given-names>BW</given-names></name>
<name><surname>Mullany</surname><given-names>P</given-names></name>
<name><surname>Fairweather</surname><given-names>NF</given-names></name>
<name><surname>Minton</surname><given-names>N</given-names></name>
</person-group>. <article-title>The multidrug resistant pathogen <italic>Clostridium difficile</italic> has a highly mobile mosaic genome</article-title>. <source>Nat Genet</source>. <year>2006</year>;<volume>38</volume>:<fpage>779</fpage>-<lpage>786</lpage>.</citation>
</ref>
<ref id="bibr33-0148607112446703">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carter</surname><given-names>GP</given-names></name>
<name><surname>Rood</surname><given-names>JI</given-names></name>
<name><surname>Lyras</surname><given-names>D</given-names></name>
</person-group>. <article-title>The role of toxin A and toxin B in the virulence of <italic>Clostridium difficile</italic></article-title>. <source>Trends Microbiol</source>. <year>2012</year>;<volume>20</volume>:<fpage>21</fpage>-<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr34-0148607112446703">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carroll</surname><given-names>KC</given-names></name>
<name><surname>Bartlett</surname><given-names>JG</given-names></name>
</person-group>. <article-title>Biology of <italic>Clostridium difficile</italic>: implications for epidemiology and diagnosis</article-title>. <source>Annu Rev Microbiol</source>. <year>2011</year>;<volume>65</volume>:<fpage>501</fpage>-<lpage>522</lpage>.</citation>
</ref>
<ref id="bibr35-0148607112446703">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jank</surname><given-names>T</given-names></name>
<name><surname>Aktories</surname><given-names>K</given-names></name>
</person-group>. <article-title>Structure and mode of action of clostridial glucosylating toxins: the ABCD model</article-title>. <source>Trends Microbiol</source>. <year>2008</year>;<volume>16</volume>:<fpage>222</fpage>-<lpage>229</lpage>.</citation>
</ref>
<ref id="bibr36-0148607112446703">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pothoulakis</surname><given-names>C</given-names></name>
</person-group>. <article-title>Effects of <italic>Clostridium difficile</italic> toxins on epithelial cell barrier</article-title>. <source>Ann NY Acad Sci</source>. <year>2000</year>;<volume>915</volume>:<fpage>347</fpage>.</citation>
</ref>
<ref id="bibr37-0148607112446703">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Geric</surname><given-names>B</given-names></name>
</person-group>. <article-title>Distribution of <italic>Clostridium difficile</italic> variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital</article-title>. <source>J Med Microbiol</source>. <year>2004</year>;<volume>53</volume>:<fpage>887</fpage>-<lpage>894</lpage>.</citation>
</ref>
<ref id="bibr38-0148607112446703">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mitchell</surname><given-names>TJ</given-names></name>
</person-group>. <article-title>Effect of toxin A and B of <italic>Clostridium difficile</italic> on rabbit ileum and colon</article-title>. <source>Gut</source>. <year>1986</year>;<volume>27</volume>:<fpage>78</fpage>-<lpage>85</lpage>.</citation>
</ref>
<ref id="bibr39-0148607112446703">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bacon</surname><given-names>AE</given-names></name>
<name><surname>Fekerty</surname><given-names>R</given-names></name>
</person-group>. <article-title>Immunoglobulin G directed against toxin A and B of <italic>Clostridium difficile</italic> in the general population and patients with antibiotic-associated diarrhea</article-title>. <source>Diagn Microbiol Infect Dis</source>. <year>1994</year>;<volume>18</volume>:<fpage>205</fpage>-<lpage>209</lpage>.</citation>
</ref>
<ref id="bibr40-0148607112446703">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Corthier</surname><given-names>G</given-names></name>
</person-group>. <article-title>Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against <italic>Clostridium difficile</italic> toxin A</article-title>. <source>Infect Immun</source>. <year>1991</year>;<volume>59</volume>:<fpage>1192</fpage>-<lpage>1195</lpage>.</citation>
</ref>
<ref id="bibr41-0148607112446703">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hamm</surname><given-names>EE</given-names></name>
</person-group>. <article-title>Identification of <italic>Clostridium difficile</italic> toxin B cardiotoxicity using zebrafish embryo model of intoxication</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2006</year>;<volume>103</volume>:<fpage>14176</fpage>-<lpage>14181</lpage>.</citation>
</ref>
<ref id="bibr42-0148607112446703">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dobson</surname><given-names>G</given-names></name>
</person-group>. <article-title><italic>Clostridium difficile</italic> colitis causing toxic megacolon, severe sepsis and multiple organ dysfunction syndrome</article-title>. <source>Intensive Med</source>. <year>2003</year>;<volume>29</volume>:<fpage>1030</fpage>-<lpage>1038</lpage>.</citation>
</ref>
<ref id="bibr43-0148607112446703">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lyas</surname><given-names>D</given-names></name>
</person-group>. <article-title>Toxin B is essential for virulence of <italic>Clostridium difficile</italic></article-title>. <source>Nature</source>. <year>2009</year>;<volume>458</volume>:<fpage>1176</fpage>-<lpage>1179</lpage>.</citation>
</ref>
<ref id="bibr44-0148607112446703">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barbut</surname><given-names>F</given-names></name>
<name><surname>Jones</surname><given-names>G</given-names></name>
<name><surname>Eckert</surname><given-names>C</given-names></name>
</person-group>. <article-title>Epidemiology and control of <italic>Clostridium difficile</italic> infections in healthcare settings: an update</article-title>. <source>Current Opinion Infect Dis</source>. <year>2011</year>;<volume>24</volume>:<fpage>370</fpage>-<lpage>376</lpage>.</citation>
</ref>
<ref id="bibr45-0148607112446703">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cheknis</surname><given-names>AK</given-names></name>
<name><surname>Sambol</surname><given-names>SP</given-names></name>
<name><surname>Davidson</surname><given-names>DM</given-names></name>
</person-group>. <article-title>Distribution of <italic>Clostridium difficile</italic> strains with other strains from a North American, European and Australian trial of treatment of <italic>C. difficile</italic> infections: 2005-2007</article-title>. <source>Anaerobe</source>. <year>2009</year>;<volume>15</volume>:<fpage>230</fpage>-<lpage>233</lpage>.</citation>
</ref>
<ref id="bibr46-0148607112446703">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bakker</surname><given-names>D</given-names></name>
<name><surname>Corver</surname><given-names>J</given-names></name>
<name><surname>Harmanus</surname><given-names>C</given-names></name>
</person-group>. <article-title>Relatedness of human and animal <italic>Clostridium difficile</italic> PCR ribotype 078 isolates determined on the basis of multilocus variable-number tandem-repeat analysis and tetracycline resistance</article-title>. <source>J Clin Microbiol</source>. <year>2010</year>;<volume>48</volume>:<fpage>3744</fpage>-<lpage>3749</lpage>.</citation>
</ref>
<ref id="bibr47-0148607112446703">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barbut</surname><given-names>FA</given-names></name>
<name><surname>Richard</surname><given-names>K</given-names></name>
<name><surname>Hamadi</surname><given-names>V</given-names></name>
<name><surname>Chomette</surname><given-names>B</given-names></name>
<name><surname>Burghoffer</surname><given-names>B</given-names></name>
<name><surname>Petit</surname><given-names>JC</given-names></name>
</person-group>. <article-title>Epidemiology of recurrence or reinfection of <italic>Clostridium difficile</italic>–associated diarrhea</article-title>. <source>J Clin Microbiol</source>. <year>2000</year>;<volume>38</volume>:<fpage>2386</fpage>-<lpage>2388</lpage>.</citation>
</ref>
<ref id="bibr48-0148607112446703">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McFarland</surname><given-names>LV</given-names></name>
<name><surname>Elmer</surname><given-names>GW</given-names></name>
<name><surname>Suawicz</surname><given-names>CM</given-names></name>
</person-group>. <article-title>Breaking the cycle treatment strategies for 163 cases of recurrent <italic>Clostridium difficile</italic> disease</article-title>. <source>Am J Gastroenterol</source>. <year>2002</year>;<volume>97</volume>:<fpage>1769</fpage>-<lpage>1775</lpage>.</citation>
</ref>
<ref id="bibr49-0148607112446703">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fawlet</surname><given-names>WNS</given-names></name>
<name><surname>S</surname><given-names>Underwood</given-names></name>
<name><surname>Freeman</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Efficacy of hospital cleaning agents and germicides against epidemic <italic>Clostridium difficile</italic> strains</article-title>. <source>Infect Control Hospi Epidemiol</source>. <year>2007</year>;<volume>28</volume>:<fpage>920</fpage>-<lpage>925</lpage>.</citation>
</ref>
<ref id="bibr50-0148607112446703">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oka</surname><given-names>K</given-names></name>
<name><surname>Osaki</surname><given-names>T</given-names></name>
<name><surname>Hanawa</surname><given-names>T</given-names></name><etal/>
</person-group>. <article-title>Molecular and microbiological characterization of <italic>Clostridium difficile</italic> isolates from single, relapse and reinfection cases</article-title>. <source>J Clin Microbiol</source>. <year>2012</year>;<volume>50</volume>(<issue>3</issue>):<fpage>915</fpage>-<lpage>921</lpage>.</citation>
</ref>
<ref id="bibr51-0148607112446703">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Permpoonpattana</surname><given-names>P</given-names></name>
<name><surname>Tolls</surname><given-names>EH</given-names></name>
<name><surname>Nadem</surname><given-names>R</given-names></name>
<name><surname>Tan</surname><given-names>S</given-names></name>
<name><surname>Brisson</surname><given-names>A</given-names></name>
<name><surname>Cutting</surname><given-names>SM</given-names></name>
</person-group>. <article-title>Surface layers of <italic>Clostridium difficile</italic> endospores</article-title>. <source>J Bacteriol</source>. <year>2011</year>;<volume>193</volume>:<fpage>6461</fpage>-<lpage>6470</lpage>.</citation>
</ref>
<ref id="bibr52-0148607112446703">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barbut</surname><given-names>F</given-names></name>
<name><surname>Petit</surname><given-names>JC</given-names></name>
</person-group>. <article-title>Epidemiology of <italic>Clostridium difficile</italic>–associated infections</article-title>. <source>Clin Microbiol Infect</source>. <year>2001</year>;<volume>7</volume>:<fpage>405</fpage>-<lpage>410</lpage>.</citation>
</ref>
<ref id="bibr53-0148607112446703">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kelly</surname><given-names>CP</given-names></name>
<name><surname>Pothoulakis</surname><given-names>C</given-names></name>
<name><surname>LaMont</surname><given-names>JT</given-names></name>
</person-group>. <article-title><italic>Clostridium difficile</italic> colitis</article-title>. <source>N Engl J Med</source>. <year>1994</year>;<volume>330</volume>:<fpage>257</fpage>-<lpage>262</lpage>.</citation>
</ref>
<ref id="bibr54-0148607112446703">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Freeman</surname><given-names>J</given-names></name>
<name><surname>Bauer</surname><given-names>MP</given-names></name>
<name><surname>Baines</surname><given-names>SD</given-names></name><etal/>
</person-group>. <article-title>The changing epidemiology of <italic>Clostridium difficile</italic> infections</article-title>. <source>Clin Microbiol Rev</source>. <year>2010</year>;<volume>23</volume>:<fpage>529</fpage>-<lpage>549</lpage>.</citation>
</ref>
<ref id="bibr55-0148607112446703">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Curry</surname><given-names>S</given-names></name>
</person-group>. <source>Clostridium difficile. Clin Lab Med</source>. <year>2010</year>;<volume>30</volume>:<fpage>329</fpage>-<lpage>342</lpage>.</citation>
</ref>
<ref id="bibr56-0148607112446703">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kee</surname><given-names>VR</given-names></name>
</person-group>. <article-title><italic>Clostridium difficile</italic> infection in older adults: a review and update on its management</article-title>. <source>Am J Geriatr Pharmacother</source>. <year>2012</year>;<volume>10</volume>:<fpage>14</fpage>-<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr57-0148607112446703">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hookman</surname><given-names>P</given-names></name>
<name><surname>Barkin</surname><given-names>JS</given-names></name>
</person-group>. <article-title><italic>Clostridium difficile</italic> associated infection, diarrhea and colitis</article-title>. <source>World J Gastroenterol</source>. <year>2009</year>;<volume>15</volume>:<fpage>1554</fpage>-<lpage>1580</lpage>.</citation>
</ref>
<ref id="bibr58-0148607112446703">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bignardi</surname><given-names>GE</given-names></name>
</person-group>. <article-title>Risk factors for <italic>Clostridium difficile</italic> infection</article-title>. <source>J Hosp Infect</source>. <year>1998</year>;<volume>40</volume>:<fpage>1</fpage>-<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr59-0148607112446703">
<label>59.</label>
<citation citation-type="gov">
<person-group person-group-type="author">
<name><surname>Butler</surname><given-names>M</given-names></name>
<name><surname>Bliss</surname><given-names>D</given-names></name>
<name><surname>Drekonja</surname><given-names>D</given-names></name><etal/>
</person-group>. <source>Effectiveness of Early Diagnosis, Prevention and Treatment of <italic>Clostridium difficile</italic> Infection</source>. Comparative Effectiveness Review No. 31 (prepared for the Minnesota Evidence-Based Practice Center under Contract No. 290-02-0009). AHRQ Publication No. 11 (12)-EHC051-EF. <publisher-loc>Rockville, MD</publisher-loc>: <publisher-name>Agency for Healthcare Research and Quality</publisher-name>; <year>2011</year>. <ext-link ext-link-type="uri" xlink:href="http://www.effectivehealthcare.ahrg.gov/index.cfm/search-for-guides-reviews-andreports/?pageaction=displayprpoduct&amp;productID=772">www.effectivehealthcare.ahrg.gov/index.cfm/search-for-guides-reviews-andreports/?pageaction=displayprpoduct&amp;productID=772</ext-link></citation>
</ref>
<ref id="bibr60-0148607112446703">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gerding</surname><given-names>DN</given-names></name>
</person-group>. <article-title>Global epidemiology of <italic>Clostridium difficile</italic> infection in 2010</article-title>. <source>Infect Control Hosp Epidemiol</source>. <year>2010</year>;<volume>31</volume>:<fpage>S32</fpage>-<lpage>S34</lpage>.</citation>
</ref>
<ref id="bibr61-0148607112446703">
<label>61.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bliss</surname><given-names>DZ</given-names></name>
<name><surname>Johnson</surname><given-names>S</given-names></name>
<name><surname>Savik</surname><given-names>K</given-names></name>
<name><surname>Clabots</surname><given-names>CR</given-names></name>
<name><surname>Willard</surname><given-names>K</given-names></name>
<name><surname>Gerding</surname><given-names>DN</given-names></name>
</person-group>. <article-title>Acquisition of <italic>Clostridium difficile</italic>–associated diarrhea in hospitalized patients receiving tube feeding</article-title>. <source>Ann Intern Med</source>. <year>1998</year>;<volume>129</volume>:<fpage>1012</fpage>-<lpage>1019</lpage>.</citation>
</ref>
<ref id="bibr62-0148607112446703">
<label>62.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lo Vecchio</surname><given-names>A</given-names></name>
<name><surname>Zacur</surname><given-names>GM</given-names></name>
</person-group>. <article-title><italic>Clostridium difficile</italic> infection: an update on epidemiology, risk factors, and therapeutic options</article-title>. <source>Curr Opin Gastroenterol</source>. <year>2012</year>;<volume>28</volume>:<fpage>1</fpage>-<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr63-0148607112446703">
<label>63.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vaishnavi</surname><given-names>C</given-names></name>
</person-group>. <article-title><italic>Clostridium difficile</italic> infection: clinical spectrum and approach to management</article-title>. <source>Indian J Gastroenterol</source>. <year>2011</year>;<volume>30</volume>:<fpage>245</fpage>-<lpage>254</lpage>.</citation>
</ref>
<ref id="bibr64-0148607112446703">
<label>64.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vaishnavi</surname><given-names>C</given-names></name>
</person-group>. <article-title>Clinical spectrum &amp; pathogenesis of <italic>Clostridium difficile</italic> associated diseases</article-title>. <source>Indian J Med Res</source>. <year>2010</year>;<volume>131</volume>:<fpage>487</fpage>-<lpage>499</lpage>.</citation>
</ref>
<ref id="bibr65-0148607112446703">
<label>65.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hurley</surname><given-names>BW</given-names></name>
<name><surname>Nguyen</surname><given-names>CC</given-names></name>
</person-group>. <article-title>The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea</article-title>. <source>Arch Intern Med</source>. <year>2002</year>;<volume>162</volume>:<fpage>2177</fpage>-<lpage>2184</lpage>.</citation>
</ref>
<ref id="bibr66-0148607112446703">
<label>66.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heinlen</surname><given-names>L</given-names></name>
<name><surname>Ballard</surname><given-names>JD</given-names></name>
</person-group>. <article-title><italic>Clostridium difficile</italic> infection</article-title>. <source>Am J Med Sci</source>. <year>2010</year>;<volume>340</volume>:<fpage>247</fpage>-<lpage>252</lpage>.</citation>
</ref>
<ref id="bibr67-0148607112446703">
<label>67.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kachrimanidou</surname><given-names>M</given-names></name>
<name><surname>Malisiovas</surname><given-names>N</given-names></name>
</person-group>. <article-title><italic>Clostridium difficile</italic> infection: a comprehensive review</article-title>. <source>Crit Rev Microbiol</source>. <year>2011</year>;<volume>37</volume>:<fpage>178</fpage>-<lpage>187</lpage>.</citation>
</ref>
<ref id="bibr68-0148607112446703">
<label>68.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Issa</surname><given-names>M</given-names></name>
<name><surname>Vijayapal</surname><given-names>A</given-names></name>
<name><surname>Graham</surname><given-names>MB</given-names></name><etal/>
</person-group>. <article-title>Impact of <italic>Clostridium difficile</italic> on inflammatory bowel disease</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2007</year>;<volume>5</volume>:<fpage>345</fpage>-<lpage>351</lpage>.</citation>
</ref>
<ref id="bibr69-0148607112446703">
<label>69.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nguyen</surname><given-names>GC</given-names></name>
<name><surname>Kaplan</surname><given-names>GG</given-names></name>
<name><surname>Harris</surname><given-names>ML</given-names></name>
<name><surname>Brant</surname><given-names>SR</given-names></name>
</person-group>. <article-title>A national survey of the prevalence and impact of <italic>Clostridium difficile</italic> infection among hospitalized inflammatory bowel disease patients</article-title>. <source>Am J Gastroenterol</source>. <year>2008</year>;<volume>103</volume>:<fpage>1443</fpage>-<lpage>1450</lpage>.</citation>
</ref>
<ref id="bibr70-0148607112446703">
<label>70.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kelly</surname><given-names>CP</given-names></name>
</person-group>. <article-title>A 76-year-old man with recurrent <italic>Clostridium difficile</italic>–associated diarrhea: review of <italic>C. difficile</italic> infection</article-title>. <source>JAMA</source>. <year>2009</year>;<volume>30</volume>:<fpage>954</fpage>-<lpage>962</lpage>.</citation>
</ref>
<ref id="bibr71-0148607112446703">
<label>71.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ananthakrishnan</surname><given-names>AN</given-names></name>
<name><surname>McGinley</surname><given-names>EL</given-names></name>
<name><surname>Binion</surname><given-names>DG</given-names></name>
</person-group>. <article-title>Excess hospitalization burden associated with <italic>Clostridium difficile</italic> in patients with inflammatory bowel disease</article-title>. <source>Gut</source>. <year>2008</year>;<volume>57</volume>:<fpage>205</fpage>-<lpage>210</lpage>.</citation>
</ref>
<ref id="bibr72-0148607112446703">
<label>72.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ananthakrishnan</surname><given-names>AN</given-names></name>
<name><surname>McGinley</surname><given-names>EL</given-names></name>
<name><surname>Saeian</surname><given-names>K</given-names></name>
<name><surname>Binion</surname><given-names>DG</given-names></name>
</person-group>. <article-title>Temporal trends in disease outcomes related to <italic>Clostridium difficile</italic> infection in patients with inflammatory bowel disease</article-title>. <source>Inflamm Bowel Dis</source>. <year>2011</year>;<volume>17</volume>:<fpage>976</fpage>-<lpage>983</lpage>.</citation>
</ref>
<ref id="bibr73-0148607112446703">
<label>73.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rolny</surname><given-names>P</given-names></name>
<name><surname>Jarnerot</surname><given-names>G</given-names></name>
<name><surname>Mollby</surname><given-names>R</given-names></name>
</person-group>. <article-title>Occurrence of <italic>Clostridium difficile</italic> toxin in inflammatory bowel disease</article-title>. <source>Scand J Gastroenterol</source>. <year>1983</year>;<volume>18</volume>:<fpage>61</fpage>-<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr74-0148607112446703">
<label>74.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rodemann</surname><given-names>JF</given-names></name>
<name><surname>Dubberke</surname><given-names>ER</given-names></name>
<name><surname>Reske</surname><given-names>KA</given-names></name>
<name><surname>Seo da</surname><given-names>H</given-names></name>
<name><surname>Stone</surname><given-names>CD</given-names></name>
</person-group>. <article-title>Incidence of <italic>Clostridium difficile</italic> infection in inflammatory bowel disease</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2007</year>;<volume>5</volume>:<fpage>339</fpage>-<lpage>344</lpage>.</citation>
</ref>
<ref id="bibr75-0148607112446703">
<label>75.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Navaneethan</surname><given-names>U</given-names></name>
<name><surname>Venkatesh</surname><given-names>PG</given-names></name>
<name><surname>Shen</surname><given-names>B</given-names></name>
</person-group>. <article-title><italic>Clostridium difficile</italic> infection and inflammatory bowel disease: understanding the evolving relationship</article-title>. <source>World J Gastroenterol</source>. <year>2010</year>;<volume>16</volume>:<fpage>4892</fpage>-<lpage>4904</lpage>.</citation>
</ref>
<ref id="bibr76-0148607112446703">
<label>76.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Clayton</surname><given-names>EM</given-names></name>
<name><surname>Rea</surname><given-names>MC</given-names></name>
<name><surname>Shanahan</surname><given-names>F</given-names></name><etal/>
</person-group>. <article-title>The vexed relationship between <italic>Clostridium difficile</italic> and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission</article-title>. <source>Am J Gastroenterol</source>. <year>2009</year>;<volume>104</volume>:<fpage>1162</fpage>-<lpage>1169</lpage>.</citation>
</ref>
<ref id="bibr77-0148607112446703">
<label>77.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bossuyt</surname><given-names>P</given-names></name>
<name><surname>Verhaegen</surname><given-names>J</given-names></name>
<name><surname>Van Assche</surname><given-names>G</given-names></name>
<name><surname>Rutgeerts</surname><given-names>P</given-names></name>
<name><surname>Vermeire</surname><given-names>S</given-names></name>
</person-group>. <article-title>Increasing incidence of <italic>Clostridium difficile</italic>–associated diarrhea in inflammatory bowel disease</article-title>. <source>J Crohns Colitis</source>. <year>2009</year>;<volume>3</volume>:<fpage>4</fpage>-<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr78-0148607112446703">
<label>78.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gellad</surname><given-names>ZF</given-names></name>
<name><surname>Alexander</surname><given-names>BD</given-names></name>
<name><surname>Liu</surname><given-names>JK</given-names></name><etal/>
</person-group>. <article-title>Severity of <italic>Clostridium difficile</italic>–associated diarrhea in solid organ transplant patients</article-title>. <source>Transplant Infect Dis</source>. <year>2007</year>;<volume>9</volume>:<fpage>276</fpage>-<lpage>280</lpage>.</citation>
</ref>
<ref id="bibr79-0148607112446703">
<label>79.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schneeweiss</surname><given-names>S</given-names></name>
<name><surname>Korzenik</surname><given-names>J</given-names></name>
<name><surname>Solomon</surname><given-names>DH</given-names></name>
<name><surname>Canning</surname><given-names>C</given-names></name>
<name><surname>Lee</surname><given-names>J</given-names></name>
<name><surname>Bressler</surname><given-names>B</given-names></name>
</person-group>. <article-title>Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2009</year>;<volume>30</volume>:<fpage>253</fpage>-<lpage>264</lpage>.</citation>
</ref>
<ref id="bibr80-0148607112446703">
<label>80.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dial</surname><given-names>S</given-names></name>
<name><surname>Delaney</surname><given-names>JA</given-names></name>
<name><surname>Barkun</surname><given-names>AN</given-names></name>
<name><surname>Suissa</surname><given-names>S</given-names></name>
</person-group>. <article-title>Use of gastric acid–suppressive agents and the risk of community-acquired <italic>Clostridium difficile</italic>–associated disease</article-title>. <source>JAMA</source>. <year>2005</year>;<volume>294</volume>:<fpage>2989</fpage>-<lpage>2995</lpage>.</citation>
</ref>
<ref id="bibr81-0148607112446703">
<label>81.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yee</surname><given-names>HF</given-names><suffix>Jr</suffix></name>
<name><surname>Brown</surname><given-names>RS</given-names><suffix>Jr</suffix></name>
<name><surname>Ostroff</surname><given-names>JW</given-names></name>
</person-group>. <article-title>Fatal <italic>Clostridium difficile</italic> enteritis after total abdominal colectomy</article-title>. <source>J Clin Gastroenterol</source>. <year>1996</year>;<volume>22</volume>:<fpage>45</fpage>-<lpage>47</lpage>.</citation>
</ref>
<ref id="bibr82-0148607112446703">
<label>82.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lundeen</surname><given-names>SJ</given-names></name>
<name><surname>Otterson</surname><given-names>MF</given-names></name>
<name><surname>Binion</surname><given-names>DG</given-names></name>
<name><surname>Carman</surname><given-names>ET</given-names></name>
<name><surname>Peppard</surname><given-names>WJ</given-names></name>
</person-group>. <article-title><italic>Clostridium difficile</italic> enteritis: an early postoperative complication in inflammatory bowel disease patients after colectomy</article-title>. <source>J Gastroenterol Surg</source>. <year>2007</year>;<volume>11</volume>:<fpage>138</fpage>-<lpage>142</lpage>.</citation>
</ref>
<ref id="bibr83-0148607112446703">
<label>83.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mann</surname><given-names>SD</given-names></name>
<name><surname>Pitt</surname><given-names>J</given-names></name>
<name><surname>Springall</surname><given-names>RG</given-names></name>
<name><surname>Thillainayagam</surname><given-names>AV</given-names></name>
</person-group>. <article-title><italic>Clostridium difficile</italic> infection—an unusual cause of refractory pouchitis: report of a case</article-title>. <source>Dis Colon Rectum</source>. <year>2003</year>;<volume>46</volume>:<fpage>267</fpage>-<lpage>270</lpage>.</citation>
</ref>
<ref id="bibr84-0148607112446703">
<label>84.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shen</surname><given-names>BO</given-names></name>
<name><surname>Jiang</surname><given-names>ZD</given-names></name>
<name><surname>Fazio</surname><given-names>VW</given-names></name><etal/>
</person-group>. <article-title><italic>Clostridium difficile</italic> infection in patients with ileal pouch–anal anastomosis</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2008</year>;<volume>6</volume>:<fpage>782</fpage>-<lpage>788</lpage>.</citation>
</ref>
<ref id="bibr85-0148607112446703">
<label>85.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Deshpande</surname><given-names>A</given-names></name>
<name><surname>Pasupuleti</surname><given-names>V</given-names></name>
<name><surname>Rolston</surname><given-names>DD</given-names></name><etal/>
</person-group>. <article-title>Diagnostic accuracy of real-time polymerase chain reaction in detection of <italic>Clostridium difficile</italic> in the stool samples of patients with suspected <italic>Clostridium difficile</italic> infection: a meta-analysis</article-title>. <source>Clin Infect Dis</source>. <year>2011</year>:<volume>53</volume>:<fpage>e81</fpage>-<lpage>e90</lpage>.</citation>
</ref>
<ref id="bibr86-0148607112446703">
<label>86.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Onderdonk</surname><given-names>AB</given-names></name>
<name><surname>Garrett</surname><given-names>WS</given-names></name>
</person-group>. <article-title>Gas gangrene and other <italic>Clostridium</italic>-associated diseases</article-title>. In: <person-group person-group-type="editor">
<name><surname>Mandell</surname><given-names>GL</given-names></name>
<name><surname>Bennett</surname><given-names>JE</given-names></name>
<name><surname>Dolin</surname><given-names>R</given-names></name>
</person-group> eds. <source>Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases</source>. <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Churchill Livingstone Elsevier</publisher-name>; <year>2009</year>.</citation>
</ref>
<ref id="bibr87-0148607112446703">
<label>87.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Stevens</surname><given-names>DL</given-names></name>
<name><surname>Bryant</surname><given-names>AE</given-names></name>
<name><surname>Berger</surname><given-names>A</given-names></name>
<name><surname>von Eichel-Streiber</surname><given-names>C</given-names></name>
</person-group>. <source>Clostridium</source>. In: <person-group person-group-type="editor">
<name><surname>Versalovic</surname><given-names>J</given-names></name>
</person-group>, ed. <source>Manual of Clinical Microbiology</source>. <edition>10th ed.</edition> <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>ASM Press</publisher-name>; <year>2011</year>.</citation>
</ref>
<ref id="bibr88-0148607112446703">
<label>88.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stamper</surname><given-names>PD</given-names></name>
<name><surname>Alcabasa</surname><given-names>R</given-names></name>
<name><surname>Aird</surname><given-names>D</given-names></name><etal/>
</person-group>. <article-title>Comparison of a commercial real-time PCR assay for <italic>tcdB</italic> detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing <italic>Clostridium difficile</italic> in clinical samples</article-title>. <source>J Clin Microbiol</source>. <year>2009</year>;<volume>47</volume>:<fpage>373</fpage>-<lpage>378</lpage>.</citation>
</ref>
<ref id="bibr89-0148607112446703">
<label>89.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schmidt</surname><given-names>ML</given-names></name>
<name><surname>Gilligan</surname><given-names>PH</given-names></name>
</person-group>. <article-title><italic>Clostridium difficile</italic> testing algorithms: what is practical and feasible?</article-title> <source>Anaerobe</source>. <year>2009</year>;<volume>15</volume>:<fpage>270</fpage>-<lpage>273</lpage>.</citation>
</ref>
<ref id="bibr90-0148607112446703">
<label>90.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Novak-Weekley</surname><given-names>SM</given-names></name>
<name><surname>Marlowe</surname><given-names>EM</given-names></name>
<name><surname>Miller</surname><given-names>JM</given-names></name><etal/>
</person-group>. <article-title><italic>Clostridium difficile</italic> testing in the clinical laboratory by use of multiple testing algorithms</article-title>. <source>J Clin Microbiol</source>. <year>2010</year>;<volume>48</volume>:<fpage>889</fpage>-<lpage>893</lpage>.</citation>
</ref>
<ref id="bibr91-0148607112446703">
<label>91.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kyne</surname><given-names>L</given-names></name>
<name><surname>Farrell</surname><given-names>RJ</given-names></name>
<name><surname>Kelly</surname><given-names>CP</given-names></name>
</person-group>. <source>Clostridium difficile. Gastroenterol Clin North Am</source>. <year>2001</year>;<volume>30</volume>:<fpage>753</fpage>-<lpage>777</lpage>.</citation>
</ref>
<ref id="bibr92-0148607112446703">
<label>92.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Girolami</surname><given-names>PC</given-names></name>
<name><surname>Hanff</surname><given-names>PA</given-names></name>
<name><surname>Eichelberger</surname><given-names>K</given-names></name><etal/>
</person-group>. <article-title>Multicenter evaluation of a new enzyme immunoassay for detection of <italic>Clostridium difficile</italic> enterotoxin A</article-title>. <source>J Clin Microbiol</source>. <year>1992</year>;<volume>30</volume>:<fpage>1085</fpage>-<lpage>1088</lpage>.</citation>
</ref>
<ref id="bibr93-0148607112446703">
<label>93.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Altaie</surname><given-names>SS</given-names></name>
<name><surname>Meyer</surname><given-names>P</given-names></name>
<name><surname>Dryja</surname><given-names>D</given-names></name>
</person-group>. <article-title>Comparison of two commercially available enzyme immunoassays for detection of <italic>Clostridium difficile</italic> in stool specimens</article-title> [published correction appears in <italic>J Clin Microbiol</italic>. 1994;32:1623]. <source>J Clin Microbiol</source>. <year>1994</year>;<volume>32</volume>:<fpage>51</fpage>-<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr94-0148607112446703">
<label>94.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Massey</surname><given-names>V</given-names></name>
<name><surname>Gregson</surname><given-names>DB</given-names></name>
<name><surname>Chagla</surname><given-names>AH</given-names></name>
<name><surname>Storey</surname><given-names>M</given-names></name>
<name><surname>John</surname><given-names>MA</given-names></name>
<name><surname>Hussain</surname><given-names>Z</given-names></name>
</person-group>. <article-title>Clinical usefulness of components of the Triage immunoassay, enzyme immunoassay for toxins A and B, and cytotoxin B tissue culture assay for the diagnosis of <italic>Clostridium difficile</italic> diarrhea</article-title>. <source>Am J Clin Pathol</source>. <year>2003</year>;<volume>119</volume>:<fpage>45</fpage>-<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr95-0148607112446703">
<label>95.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eastwood</surname><given-names>K</given-names></name>
<name><surname>Else</surname><given-names>P</given-names></name>
<name><surname>Charlett</surname><given-names>A</given-names></name>
<name><surname>Wilcox</surname><given-names>M</given-names></name>
</person-group>. <article-title>Comparison of nine commercially available <italic>Clostridium difficile</italic> toxin detection assays, a real-time PCR assay for <italic>C. difficile tcdB</italic>, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods</article-title>. <source>J Clin Microbiol</source>. <year>2009</year>;<volume>47</volume>:<fpage>3211</fpage>-<lpage>3217</lpage>.</citation>
</ref>
<ref id="bibr96-0148607112446703">
<label>96.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Orendi</surname><given-names>JM</given-names></name>
<name><surname>Monnery</surname><given-names>DJ</given-names></name>
<name><surname>Manzoor</surname><given-names>S</given-names></name>
<name><surname>Hawkey</surname><given-names>PM</given-names></name>
</person-group>. <article-title>A two-stage algorithm for <italic>Clostridium difficile</italic> including PCR: can we replace the toxin EIA?</article-title> <source>J Hosp Infect</source>. <year>2012</year>;<volume>80</volume>:<fpage>82</fpage>-<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr97-0148607112446703">
<label>97.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goldenberg</surname><given-names>SD</given-names></name>
<name><surname>Cliff</surname><given-names>PR</given-names></name>
<name><surname>Smith</surname><given-names>S</given-names></name>
<name><surname>Milner</surname><given-names>M</given-names></name>
<name><surname>French</surname><given-names>GL</given-names></name>
</person-group>. <article-title>Two-step glutamate dehydrogenase antigen real-time polymerase chain reaction assay for detection of toxigenic <italic>Clostridium difficile</italic></article-title>. <source>J Hosp Infect</source>. <year>2010</year>;<volume>74</volume>:<fpage>48</fpage>-<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr98-0148607112446703">
<label>98.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carroll</surname><given-names>KC</given-names></name>
</person-group>. <article-title>Tests for the diagnosis of <italic>Clostridium difficile</italic> infection: the next generation</article-title>. <source>Anaerobe</source>. <year>2011</year>;<volume>17</volume>:<fpage>170</fpage>-<lpage>174</lpage>.</citation>
</ref>
<ref id="bibr99-0148607112446703">
<label>99.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reller</surname><given-names>ME</given-names></name>
<name><surname>Lema</surname><given-names>CA</given-names></name>
<name><surname>Perl</surname><given-names>TA</given-names></name><etal/>
</person-group>. <article-title>Yield of stool culture with isolate toxin testing versus a two-step algorithm including stool toxin testing for detection of toxigenic <italic>Clostridium difficile</italic></article-title>. <source>J Clin Microbiol</source>. <year>2007</year>;<volume>45</volume>:<fpage>3601</fpage>-<lpage>3605</lpage>.</citation>
</ref>
<ref id="bibr100-0148607112446703">
<label>100.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fenner</surname><given-names>L</given-names></name>
<name><surname>Widmer</surname><given-names>AF</given-names></name>
<name><surname>Goy</surname><given-names>G</given-names></name>
<name><surname>Rudin</surname><given-names>S</given-names></name>
<name><surname>Frei</surname><given-names>R</given-names></name>
</person-group>. <article-title>Rapid and reliable diagnostic algorithm for detection of <italic>Clostridium difficile</italic></article-title>. <source>J Clin Microbiol</source>. <year>2008</year>;<volume>46</volume>:<fpage>328</fpage>-<lpage>330</lpage>.</citation>
</ref>
<ref id="bibr101-0148607112446703">
<label>101.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>L</given-names></name>
<name><surname>Keller</surname><given-names>SF</given-names></name>
<name><surname>Lyerly</surname><given-names>DM</given-names></name><etal/>
</person-group>. <article-title>Multicenter evaluation of a new screening test that detects <italic>Clostridium difficile</italic> in fecal specimens</article-title>. <source>J Clin Microbiol</source>. <year>2004</year>;<volume>42</volume>:<fpage>3837</fpage>-<lpage>3840</lpage>.</citation>
</ref>
<ref id="bibr102-0148607112446703">
<label>102.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Snell</surname><given-names>H</given-names></name>
<name><surname>Ramos</surname><given-names>M</given-names></name>
<name><surname>Longo</surname><given-names>S</given-names></name>
<name><surname>John</surname><given-names>M</given-names></name>
<name><surname>Hussain</surname><given-names>Z</given-names></name>
</person-group>. <article-title>Performance of the TechLab C DIFF CHEK-60 enzyme immunoassay (EIA) in combination with the <italic>C. difficile</italic> Tox A/B II EIA kit, the Triage <italic>C. difficile</italic> panel immunoassay, and a cytotoxin assay for diagnosis of <italic>Clostridium difficile</italic>–associated diarrhea</article-title>. <source>J Clin Microbiol</source>. <year>2004</year>;<volume>42</volume>:<fpage>4863</fpage>-<lpage>4865</lpage>.</citation>
</ref>
<ref id="bibr103-0148607112446703">
<label>103.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ticehurst</surname><given-names>JR</given-names></name>
<name><surname>Aird</surname><given-names>DZ</given-names></name>
<name><surname>Dam</surname><given-names>LM</given-names></name>
<name><surname>Borek</surname><given-names>AP</given-names></name>
<name><surname>Hargrove</surname><given-names>JT</given-names></name>
<name><surname>Carroll</surname><given-names>KC</given-names></name>
</person-group>. <article-title>Effective detection of toxigenic <italic>Clostridium difficile</italic> by a two-step algorithm including tests for antigen and cytotoxin</article-title>. <source>J Clin Microbiol</source>. <year>2006</year>;<volume>44</volume>:<fpage>1145</fpage>-<lpage>1149</lpage>.</citation>
</ref>
<ref id="bibr104-0148607112446703">
<label>104.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kato</surname><given-names>N</given-names></name>
<name><surname>Ou</surname><given-names>CY</given-names></name>
<name><surname>Kato</surname><given-names>H</given-names></name><etal/>
</person-group>. <article-title>Detection of toxigenic <italic>Clostridium difficile</italic> in stool specimens by the polymerase chain reaction</article-title>. <source>J Infect Dis</source>. <year>1993</year>;<volume>167</volume>:<fpage>455</fpage>-<lpage>458</lpage>.</citation>
</ref>
<ref id="bibr105-0148607112446703">
<label>105.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kuhl</surname><given-names>SJ</given-names></name>
<name><surname>Tang</surname><given-names>YJ</given-names></name>
<name><surname>Navarro</surname><given-names>L</given-names></name>
<name><surname>Gummerlock</surname><given-names>PH</given-names></name>
<name><surname>Silva</surname><given-names>J</given-names></name>
</person-group>. <article-title>Diagnosis and monitoring of <italic>Clostridium difficile</italic> infections with the polymerase chain reaction</article-title>. <source>Clin Infect Dis</source>. <year>1993</year>;<volume>16</volume>:<fpage>S234</fpage>-<lpage>S238</lpage>.</citation>
</ref>
<ref id="bibr106-0148607112446703">
<label>106.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Selvaraju</surname><given-names>SB</given-names></name>
<name><surname>Gripka</surname><given-names>M</given-names></name>
<name><surname>Estes</surname><given-names>K</given-names></name>
<name><surname>Nguyen</surname><given-names>A</given-names></name>
<name><surname>Jackson</surname><given-names>MA</given-names></name>
<name><surname>Selvarangan</surname><given-names>R</given-names></name>
</person-group>. <article-title>Detection of toxigenic <italic>Clostridium difficile</italic> in pediatric stool samples: an evaluation of Quik Check Complete Antigen assay, BD GeneOhm Cdiff PCR, and ProGastro Cd PCR assays</article-title>. <source>Diagn Microbiol Infect Dis</source>. <year>2011</year>;<volume>71</volume>(<issue>3</issue>):<fpage>224</fpage>-<lpage>229</lpage>.</citation>
</ref>
<ref id="bibr107-0148607112446703">
<label>107.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stamper</surname><given-names>PD</given-names></name>
<name><surname>Babiker</surname><given-names>W</given-names></name>
<name><surname>Alcabasa</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Evaluation of a new commercial TaqMan PCR assay for direct detection of the <italic>Clostridium difficile</italic> toxin B gene in clinical stool specimens</article-title>. <source>J Clin Microbiol</source>. <year>2009</year>;<volume>47</volume>:<fpage>3846</fpage>-<lpage>3850</lpage>.</citation>
</ref>
<ref id="bibr108-0148607112446703">
<label>108.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Doing</surname><given-names>KM</given-names></name>
<name><surname>Hintz</surname><given-names>MS</given-names></name>
</person-group>. <article-title>Prospective evaluation of the Meridian Illumigene™ loop-mediated amplification assay and the Gen Probe ProGastro™ Cd polymerase chain reaction assay for the direct detection of toxigenic <italic>Clostridium difficile</italic> from fecal samples</article-title>. <source>Diagn Microbiol Infect Dis</source>. <year>2012</year>;<volume>72</volume>:<fpage>8</fpage>-<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr109-0148607112446703">
<label>109.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boyanton</surname><given-names>BL</given-names><suffix>Jr</suffix></name>
<name><surname>Sural</surname><given-names>P</given-names></name>
<name><surname>Loomis</surname><given-names>CR</given-names></name><etal/>
</person-group>. <article-title>Loop-mediated isothermal amplification compared to real-time PCR and enzyme immunoassay for toxigenic <italic>C. difficile</italic> detection</article-title>. <source>J Clin Microbiol</source>. <year>2012</year>;<volume>502</volume>(<issue>3</issue>):<fpage>640</fpage>-<lpage>645</lpage>.</citation>
</ref>
<ref id="bibr110-0148607112446703">
<label>110.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>SH</given-names></name>
<name><surname>Gerding</surname><given-names>DN</given-names></name>
<name><surname>Johnson</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>Clinical practice guidelines for <italic>Clostridium difficile</italic> infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)</article-title>. <source>Infect Control Hosp Epidemiol</source>. <year>2010</year>;<volume>1</volume>:<fpage>431</fpage>-<lpage>455</lpage>.</citation>
</ref>
<ref id="bibr111-0148607112446703">
<label>111.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aichinger</surname><given-names>E</given-names></name>
<name><surname>Schleck</surname><given-names>CD</given-names></name>
<name><surname>Harmsen</surname><given-names>WS</given-names></name><etal/>
</person-group>. <article-title>Nonunity of repeat laboratory testing for detection of <italic>Clostridium difficile</italic> by use of PCR or enzyme immunoassay</article-title>. <source>J Clin Microbiol</source>. <year>2008</year>;<volume>46</volume>:<fpage>3795</fpage>-<lpage>3797</lpage>.</citation>
</ref>
<ref id="bibr112-0148607112446703">
<label>112.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fong</surname><given-names>KS</given-names></name>
<name><surname>Fatica</surname><given-names>C</given-names></name>
<name><surname>Hall</surname><given-names>G</given-names></name><etal/>
</person-group>. <article-title>Impact of PCR testing for <italic>Clostridium difficile</italic> on incident rates and potential on public reporting: is the playing field level?</article-title> <source>Infect Control Hosp Epidemiol</source>. <year>2011</year>;<volume>32</volume>:<fpage>932</fpage>-<lpage>933</lpage>.</citation>
</ref>
<ref id="bibr113-0148607112446703">
<label>113.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zar</surname><given-names>F</given-names></name>
<name><surname>Bakkanagari</surname><given-names>S</given-names></name>
<name><surname>Moorthi</surname><given-names>K</given-names></name><etal/>
</person-group>. <article-title>A comparison of vancomycin and metronidazole for the treatment of <italic>Clostridium difficile</italic> associated diarrhea, stratified by disease severity</article-title>. <source>Clin Infect Dis</source>. <year>2007</year>;<volume>45</volume>:<fpage>302</fpage>-<lpage>307</lpage>.</citation>
</ref>
<ref id="bibr114-0148607112446703">
<label>114.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McFarland</surname><given-names>LV</given-names></name>
</person-group>. <article-title>Alternative treatments for <italic>Clostridium difficile</italic> disease: what really works?</article-title> <source>J Med Microbiol</source>. <year>2005</year>;<volume>54</volume>:<fpage>101</fpage>-<lpage>111</lpage>.</citation>
</ref>
<ref id="bibr115-0148607112446703">
<label>115.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>DuPont</surname></name>
</person-group>. <article-title>The search for effective treatment of <italic>Clostridium difficile</italic> infection</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>364</volume>:<fpage>473</fpage>-<lpage>475</lpage>.</citation>
</ref>
<ref id="bibr116-0148607112446703">
<label>116.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>S</given-names></name>
<name><surname>Schriever</surname><given-names>C</given-names></name>
<name><surname>Galang</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Interruption of recurrent <italic>Clostridium difficile</italic>–associated diarrhea episodes by serial therapy with vancomycin and rifaximin</article-title>. <source>Clin Infect Dis</source>. <year>2007</year>;<volume>44</volume>:<fpage>846</fpage>-<lpage>848</lpage>.</citation>
</ref>
<ref id="bibr117-0148607112446703">
<label>117.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Griffin</surname><given-names>AT</given-names></name>
<name><surname>Arnold</surname><given-names>FW</given-names></name>
</person-group>. <article-title>The most effective treatments for <italic>Clostridium difficile</italic> diarrhea: an evidence-based review</article-title>. <source>Infect Dis Clin Pract</source>. <year>2011</year>;<volume>19</volume>:<fpage>171</fpage>-<lpage>181</lpage>.</citation>
</ref>
<ref id="bibr118-0148607112446703">
<label>118.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Neff</surname><given-names>G</given-names></name>
<name><surname>Zacharias</surname><given-names>V</given-names></name>
<name><surname>Kaiser</surname><given-names>TE</given-names></name><etal/>
</person-group>. <article-title>Rifaximin for the treatment of recurrent <italic>Clostridium difficile</italic> infection after liver transplantation: a case series</article-title>. <source>Liver Transplantation</source>. <year>2010</year>;<volume>16</volume>:<fpage>960</fpage>-<lpage>963</lpage>.</citation>
</ref>
<ref id="bibr119-0148607112446703">
<label>119.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garey</surname><given-names>KW</given-names></name>
<name><surname>Jiang</surname><given-names>ZD</given-names></name>
<name><surname>Bellard</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Rifaximin in treatment of recurrent <italic>Clostridium difficile</italic>–associated diarrhea: an uncontrolled pilot study</article-title>. <source>J Clin Gastroenterol</source>. <year>2009</year>;<volume>43</volume>:<fpage>91</fpage>-<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr120-0148607112446703">
<label>120.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Louie</surname><given-names>TJ</given-names></name>
<name><surname>Miller</surname><given-names>MA</given-names></name>
<name><surname>Mullane</surname><given-names>KM</given-names></name><etal/>
</person-group>. <article-title>Fidaxomicin versus vancomycin for <italic>Clostridium difficile</italic> infection</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>364</volume>:<fpage>422</fpage>-<lpage>431</lpage>.</citation>
</ref>
<ref id="bibr121-0148607112446703">
<label>121.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miller</surname><given-names>M</given-names></name>
</person-group>. <article-title>Fidaxomicin (OPT-80) for the treatment of <italic>Clostridium difficile</italic> infection</article-title>. <source>Expert Opin Pharmacother</source>. <year>2010</year>;<volume>11</volume>:<fpage>1569</fpage>-<lpage>1578</lpage>.</citation>
</ref>
<ref id="bibr122-0148607112446703">
<label>122.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Peláez</surname><given-names>TA</given-names></name>
<name><surname>Rodriquez-Creixems</surname><given-names>M</given-names></name>
<name><surname>Garcia-Lechuz</surname><given-names>JM</given-names></name><etal/>
</person-group>. <article-title>Reassessment of <italic>Clostridium difficile</italic> susceptibility to metronidazole and vancomycin</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2002</year>;<volume>46</volume>:<fpage>1647</fpage>-<lpage>1650</lpage>.</citation>
</ref>
<ref id="bibr123-0148607112446703">
<label>123.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Musher</surname><given-names>DM</given-names></name>
<name><surname>Logan</surname><given-names>N</given-names></name>
<name><surname>Bressler</surname><given-names>AM</given-names></name><etal/>
</person-group>. <article-title>Nitazoxanide versus vancomycin in <italic>Clostridium difficile</italic> infection: a randomized, double-blind study</article-title>. <source>Clin Infect Dis</source>. <year>2009</year>;<volume>48</volume>:<fpage>e41</fpage>-<lpage>e46</lpage>.</citation>
</ref>
<ref id="bibr124-0148607112446703">
<label>124.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Herpers</surname><given-names>BL</given-names></name>
<name><surname>Vlaminckx</surname><given-names>B</given-names></name>
<name><surname>Burkhardt</surname><given-names>O</given-names></name><etal/>
</person-group>. <article-title>Intravenous tigecycline as adjunctive or alternative therapy for severe refractory <italic>Clostridium difficile</italic> infection</article-title>. <source>Clin Infect Dis</source>. <year>2009</year>;<volume>48</volume>:<fpage>1732</fpage>-<lpage>1735</lpage>.</citation>
</ref>
<ref id="bibr125-0148607112446703">
<label>125.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Larson</surname><given-names>KC</given-names></name>
<name><surname>Belliveau</surname><given-names>PP</given-names></name>
<name><surname>Spooner</surname><given-names>LM</given-names></name><etal/>
</person-group>. <article-title>Tigecycline for the treatment of severe <italic>Clostridium difficile</italic> infection</article-title>. <source>Ann Pharmacother</source>. <year>2011</year>;<volume>45</volume>:<fpage>1005</fpage>-<lpage>1010</lpage>.</citation>
</ref>
<ref id="bibr126-0148607112446703">
<label>126.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Drekonja</surname><given-names>DM</given-names></name>
<name><surname>Butler</surname><given-names>M</given-names></name>
<name><surname>MacDonald</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Comparative effectiveness of <italic>Clostridium difficile</italic> treatments: a systematic review</article-title>. <source>Ann Intern Med</source>. <year>2011</year>;<volume>155</volume>:<fpage>839</fpage>-<lpage>847</lpage>.</citation>
</ref>
<ref id="bibr127-0148607112446703">
<label>127.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pillai</surname><given-names>A</given-names></name>
<name><surname>Nelson</surname><given-names>RL</given-names></name>
</person-group>. <article-title>Probiotics for treatment of <italic>Clostridium difficile</italic>–associated colitis in adults</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2008</year>;(<issue>1</issue>):CD004611.</citation>
</ref>
<ref id="bibr128-0148607112446703">
<label>128.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McFarland</surname><given-names>LV</given-names></name>
</person-group>. <article-title>Systematic review and meta-analysis of <italic>Saccharomyces boulardii</italic> in adult patients</article-title>. <source>World J Gastroenterol</source>. <year>2010</year>;<volume>16</volume>(<issue>18</issue>):<fpage>2202</fpage>-<lpage>2222</lpage>.</citation>
</ref>
<ref id="bibr129-0148607112446703">
<label>129.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abougergi</surname><given-names>MS</given-names></name>
<name><surname>Kwon</surname><given-names>JH</given-names></name>
</person-group>. <article-title>Intravenous immunoglobulin for the treatment of <italic>Clostridium difficile</italic> infection: a review</article-title>. <source>Digest Dis Sci</source>. <year>2011</year>;<volume>56</volume>:<fpage>19</fpage>-<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr130-0148607112446703">
<label>130.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Horo</surname><given-names>J</given-names></name>
<name><surname>Safdar</surname><given-names>N</given-names></name>
</person-group>. <article-title>The role of immunoglobulin for the treatment of <italic>Clostridium difficile</italic> infection: a systematic review</article-title>. <source>Int J Infect Dis</source>. <year>2009</year>;<volume>13</volume>:<fpage>663</fpage>-<lpage>667</lpage>.</citation>
</ref>
<ref id="bibr131-0148607112446703">
<label>131.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lowy</surname><given-names>I</given-names></name>
<name><surname>Molrine</surname><given-names>DC</given-names></name>
<name><surname>Leav</surname><given-names>BA</given-names></name><etal/>
</person-group>. <article-title>Treatment with monoclonal antibodies against <italic>Clostridium difficile</italic> toxins</article-title>. <source>N Engl J Med</source>. <year>2010</year>;<volume>362</volume>:<fpage>197</fpage>-<lpage>205</lpage>.</citation>
</ref>
<ref id="bibr132-0148607112446703">
<label>132.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yoon</surname><given-names>SS</given-names></name>
<name><surname>Brandt</surname><given-names>LJ</given-names></name>
</person-group>. <article-title>Treatment of refractory/recurrent <italic>C. difficile</italic>–associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients</article-title>. <source>J Clin Gastroenterol</source>. <year>2010</year>;<volume>44</volume>:<fpage>562</fpage>-<lpage>566</lpage>.</citation>
</ref>
<ref id="bibr133-0148607112446703">
<label>133.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gough</surname><given-names>E</given-names></name>
<name><surname>Shaikh</surname><given-names>H</given-names></name>
<name><surname>Manges</surname><given-names>AR</given-names></name>
</person-group>. <article-title>Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent infection</article-title>. <source>Clin Infect Dis</source>. <year>2011</year>;<volume>53</volume>:<fpage>994</fpage>-<lpage>1002</lpage>.</citation>
</ref>
<ref id="bibr134-0148607112446703">
<label>134.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Siegel</surname><given-names>JD</given-names></name>
<name><surname>Rhinehart</surname><given-names>E</given-names></name>
<name><surname>Jackson</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>2007 Guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Health Care Infection Control Practices Advisory Committee</article-title>. <source>Am J Infect Control</source>. <year>2007</year>;<volume>35</volume>:<fpage>S65</fpage>-<lpage>S164</lpage>.</citation>
</ref>
<ref id="bibr135-0148607112446703">
<label>135.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hamel</surname><given-names>M</given-names></name>
<name><surname>Zoutman</surname><given-names>D</given-names></name>
<name><surname>O’Callaghan</surname><given-names>C</given-names></name>
</person-group>. <article-title>Exposure to hospital roommates as a risk factor for health care–associated infection</article-title>. <source>Am J Infect Control</source>. <year>2010</year>;<volume>38</volume>:<fpage>173</fpage>-<lpage>181</lpage>.</citation>
</ref>
<ref id="bibr136-0148607112446703">
<label>136.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rebmann</surname><given-names>T</given-names></name>
<name><surname>Carrico</surname><given-names>RM</given-names></name>
</person-group>; <collab>Association for Professionals in Infection Control and Epidemiology</collab>. <article-title>Preventing <italic>Clostridium difficile</italic> infections: an executive summary of the Association for Professionals in Infection Control and Epidemiology’s elimination guide</article-title>. <source>Am J Infect Control</source>. <year>2011</year>;<volume>39</volume>:<fpage>239</fpage>-<lpage>242</lpage>.</citation>
</ref>
<ref id="bibr137-0148607112446703">
<label>137.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weber</surname><given-names>DJ</given-names></name>
<name><surname>Rutala</surname><given-names>WA</given-names></name>
</person-group>. <article-title>The role of the environment in transmission of <italic>Clostridium difficile</italic> infection in healthcare facilities</article-title>. <source>Infect Control Hosp Epidemiol</source>. <year>2011</year>;<volume>32</volume>:<fpage>207</fpage>-<lpage>209</lpage>.</citation>
</ref>
<ref id="bibr138-0148607112446703">
<label>138.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gerding</surname><given-names>DN</given-names></name>
<name><surname>Muto</surname><given-names>CA</given-names></name>
<name><surname>Owens</surname><given-names>RC</given-names></name>
</person-group>. <article-title>Measures to control and prevent <italic>Clostridium difficile</italic> infection</article-title>. <source>Clin Infect Dis</source>. <year>2008</year>;<volume>46</volume>:<fpage>S43</fpage>-<lpage>S49</lpage>.</citation>
</ref>
<ref id="bibr139-0148607112446703">
<label>139.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boyce</surname><given-names>JM</given-names></name>
<name><surname>Pittet</surname><given-names>D</given-names></name>
</person-group>. <article-title>Guideline for hand hygiene in health-care settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HIPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Healthcare Infection Control Practices Advisory Committee; HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force</article-title>. <source>Am J Infect Control</source>. <year>2002</year>;<volume>30</volume>:<fpage>S1</fpage>-<lpage>S46</lpage>.</citation>
</ref>
<ref id="bibr140-0148607112446703">
<label>140.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boyce</surname><given-names>JM</given-names></name>
</person-group>. <article-title>Environmental contamination makes an important contribution to hospital infection</article-title>. <source>J Hosp Infect</source>. <year>2007</year>;<volume>65</volume>:<fpage>50</fpage>-<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr141-0148607112446703">
<label>141.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gerding</surname><given-names>DN</given-names></name>
<name><surname>Johnson</surname><given-names>S</given-names></name>
<name><surname>Peterson</surname><given-names>LR</given-names></name>
<name><surname>Mulligan</surname><given-names>ME</given-names></name>
<name><surname>Silva</surname><given-names>J</given-names></name>
</person-group>. <article-title><italic>Clostridium difficile</italic>–associated diarrhea and colitis</article-title>. <source>Infect Control Hosp Epidemiol</source>. <year>1995</year>;<volume>16</volume>:<fpage>459</fpage>-<lpage>477</lpage>.</citation>
</ref>
<ref id="bibr142-0148607112446703">
<label>142.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carter</surname><given-names>Y</given-names></name>
<name><surname>Barry</surname><given-names>D</given-names></name>
</person-group>. <article-title>Tackling <italic>C difficile</italic> with environmental cleaning</article-title>. <source>Nurs Times</source>. <year>2011</year>;<volume>107</volume>:<fpage>22</fpage>-<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr143-0148607112446703">
<label>143.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dubberke</surname><given-names>ER</given-names><suffix>Jr</suffix></name>
<name><surname>Nyazee</surname><given-names>HA</given-names></name>
<name><surname>Yokoe</surname><given-names>DS</given-names></name><etal/>
</person-group>. <article-title>Implementing automated surveillance for tracking <italic>Clostridium difficile</italic> infection at multiple healthcare facilities</article-title>. <source>Infect Control Hosp Epidemiol</source>. <year>2012</year>;<volume>33</volume>:<fpage>305</fpage>-<lpage>308</lpage>.</citation>
</ref>
<ref id="bibr144-0148607112446703">
<label>144.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dallal</surname><given-names>RM</given-names></name>
<name><surname>Harbrecht</surname><given-names>BG</given-names></name>
<name><surname>Boujoukas</surname><given-names>AJ</given-names></name><etal/>
</person-group>. <article-title>Fulminant <italic>Clostridium difficile</italic>: an underappreciated and increasing cause of death and complications</article-title>. <source>Ann Surg</source>. <year>2002</year>;<volume>235</volume>:<fpage>363</fpage>-<lpage>372</lpage>.</citation>
</ref>
<ref id="bibr145-0148607112446703">
<label>145.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bartlett</surname><given-names>JG</given-names></name>
</person-group>. <article-title>A call to arms: the imperative for antimicrobial stewardship</article-title>. <source>Clin Infect Dis</source>. <year>2011</year>;<volume>53</volume>:<fpage>S4</fpage>-<lpage>S7</lpage>.</citation>
</ref>
<ref id="bibr146-0148607112446703">
<label>146.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Talpaert</surname><given-names>MJ</given-names></name>
<name><surname>Gopal Rao</surname><given-names>G</given-names></name>
<name><surname>Cooper</surname><given-names>BS</given-names></name>
<name><surname>Wade</surname><given-names>P</given-names></name>
</person-group>. <article-title>Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of <italic>Clostridium difficile</italic> infection</article-title>. <source>J Antimicrob Chemother</source>. <year>2011</year>;<volume>66</volume>:<fpage>2168</fpage>-<lpage>2174</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>